Information
-
Patent Application
-
20040147557
-
Publication Number
20040147557
-
Date Filed
December 01, 200321 years ago
-
Date Published
July 29, 200420 years ago
-
CPC
-
US Classifications
-
International Classifications
- A61K031/454
- A61K031/452
- A61K031/445
Abstract
The invention relates to a compound of formula (I), wherein Ar1 represents phenyl, naphthyl or phenyl fused by a C3-8cycloalkyl, where each group is optionally substituted by methylenedioxy or one or two groups independently represented by R1; Ar2 represents phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from halogen, C1-4 alkyl and C1-4 alkoxy; Ar3 represents a phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from hydroxy, alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkenyloxy, C1-4 perfluoroalkoxy, C1-4 acylamino or an electron withdrawing group; A represents —C(H)—; E represents —C1-6 alkylene-; X represents —CON(H or C1-4alkyl)- or —N(H or C1-4alkyl)CO—; Y represents a direct link; R1 represents halogen, —S(C1-4 alkyl)-, —O—(C0-4 alkylene)-R2 or —(C0-4alkylene)-R2, where each alkylene group may additionally incorporate an oxygen in the chain, with the proviso that there are at least two carbon atoms between any chain heteroatoms; R2 represents: i) hydrogen, C1-4 perfluoroalkyl, C2-3 alkenyl, ii) phenyl, naphthyl, a 5- or 6-membered heteroaromatic group or 1,2,3,4-tetrahydronaphthyl, optionally substituted by one or two halogen, hydroxy, C1-4 alkyl, C1-4 alkoxy groups, iii) C3-8cycloalkyl, a 3-7 membered heterocycloalkyl, iv) amino, C1-4 alkylamino or di-C1-4alkylamino, with the proviso that there are at least two carbon atoms between any chain heteroatoms; to salts, solvates and compositions thereof and their use in treating disorders associated with elevated levels of circulating LDL-cholesterol.
1
Description
[0001] This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines and their use in therapy.
[0002] Epidemiological studies have clearly demonstrated the correlation between reduction in plasmatic LDL cholesterol and the benefit on cardiovascular events including mortality. LDL cholesterol is eliminated from plasma by specific binding to LDL-r expressed by the liver. Regulation of LDL-r expression occurs in the liver and is mainly dependent on intracellular cholesterol concentration. Increasing free cholesterol concentration leads to a reduced LDL-r expression through a mechanism involving transcriptional factors. Counteracting with this process is expected to up-regulate LDL-r expression in the liver and to increase the clearance of LDL cholesterol.
[0003] International Patent Application Number PCT.EP00.06668 concerns the novel use of the SREBP-cleavage activating protein (SCAP) in a screening method, and two compounds are disclosed, namely 4-(4-chloro-benzoylamino)-N-{4-[4-(2-ethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-benzamide and 4-(4-Benzoyl)-N-{4-[4-(4-isopropyl-2-methoxy-phenyl)-piperidin-1-yl]-butyl}-benzamide hydrochloride, which do not form part of the present invention.
[0004] Another publication, Bioorganic and Medicinal Chemistry Letters Vol. 5, 3, 219-222, 1995 discloses compounds having the general formula (A)
2
[0005] where X may be COMe, SO2Me and NH2, as having high affinity for the dopamine D3 receptor and postulates their use in CNS disorders, particularly psychiatric illness. The compound of formula A where X is COMe is also disclosed in J.Pharmacol. Exp. Ther. 287; 1 1998 187-197 and Bioorganic and Medicinal Chemistry Letters Vol. 7, 15, 1995-1998, 1997, again as being useful in treating CNS disorders. It will be noted that the examples of the present invention differ from those of formula (A) in use of a piperidine ring rather than a piperazine and in the utility disclosed.
[0006] Journal Of Medicinal Chemistry, Vol. 40, 6, 952-960, 1997 discloses compounds of formula (B)
3
[0007] where m=0, 1 or 2; n=2 or 3; R1 and R3=H or OMe and R2 may be Ph, as selective 5-HT1A receptor ligands having CNS activity. It will be noted that the examples of the present invention differ from those of formula (B) in use of a piperidine ring rather than a piperazine and in the utility disclosed.
[0008] International Patent Application Publication Number WO99/45925 discloses compounds of formula (C)
4
[0009] where R1 may be hydrogen, R2 may be hydrogen and R3 may be a group
5
[0010] where X may be an aryl group and n may be 1. Specifically disclosed are compounds where the group COR3 is formed from 2- and 4-biphenyl carboxylic acid and R1 and R2 are methyl or hydrogen respectively. The utility of the compounds is as opioid receptor binding agents which may be useful as analgesics. The substitution on the 3- and 4-positions of the piperidine ring leave the compounds of this publication outside the scope of the present invention. Furhtermore, the utility disclosed is different.
[0011] International Patent Application Publication Number WO98/37893 discloses compounds of formula (D)
6
[0012] where Ar may represent an optionally substituted phenyl or naphthyl, G may be N or CH2 (sic), W may be an optionally substituted alkylene, Y may be hydrogen and Z may represent a group R4CONR5, where R4 may be an optionally substituted phenyl and R5 may be hydrogen. These compounds are described as being D2 receptor antagonists useful in the treatment of CNS disorders such as Parkinson's Disease. None of the compounds specifically disclosed fall within the scope of the present invention and the disclosed utlity is different.
[0013] International Patent Application Publication Number WO9402473 discloses compounds of formula (E)
7
[0014] where A may be NHCO or CONH; R1-R5 may be hydrogen or a benzene ring, m may be 1-3 and n may be 1-3. Specifically disclosed are compounds
1|
|
No.AnmR1R2R3R4R5
|
5NHCO21HHPhHH
12NHCO22HHPhHH
19NHCO23HHPhHH
|
[0015] The compounds are described as 5HT-1A agonists having CNS activity and may be used as anti-depressants, anti-hypertensive, analgesics etc. It will be noted that the examples of the present invention differ from those of formula (E) in use of a piperidine ring rather than a piperazine and in the utility disclosed.
[0016] International Patent Application Publication Number WO99/45925 discloses compounds of formula (F)
8
[0017] where A may represent a substituted phenyl group, W represents a linear or branched alkylene group having from 2 to 6 carbon atoms; Y may represent a group NHCO or CONH; and R may be a substituted phenyl group. Particularly disclosed is the compound G
9
[0018] These compounds are described as being α1A-adrenergic receptors useful in the treatment of contractions of the prostate, urethra and lower urinary tract, without affecting blood pressure. It will be noted that the examples of the present invention differ from those of formula (G) in use of a piperidine ring rather than a piperazine and in the utility disclosed.
[0019] International Patent Application Publication Number WO98/35957 describes compounds of formula (H)
10
[0020] wherein R1-R5 are each individually selected from the group of substituents including hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl, nitro and cyano. Specifically disclosed compounds are those formed by the N-alkylation of a a substituted piperidine or piperazine with a group (J)
11
[0021] where X is a leaving group. None of the compounds specifically disclosed fall within the scope of the present invention and the invention is in no way suggested by the disclosure. The compounds are said to be of use as NPY Y5 receptor antagonists in the treatment of obesity, bulemia and related disorders and NPY Y5 receptor inhibition related disorders such as memory disorders, epilepsy, dyslipidemia and depression. U.S. Pat. No. 6,048,900, published after the priority date of the present invention discloses the same information.
[0022] Journal Of Medicinal Chemistry, Vol. 31, 1968-1971, 1988 discloses certain aryl piperazines compounds, which fall outside the present invention, as 5HT-1a Serotonin Ligands as potential CNS agents. Specifically disclosed are compounds of formula (K)
12
[0023] where Ar=Ph and R=Ph, Ar=2-OMePh and R=Ph and Ar=2-pyrimidyl and R=Ph.
[0024] Journal Of Medicinal Chemistry, Vol. 34, 2633-2638, 1991 discloses aryl piperazines having reduced α1 adrenergic affinity. Specifically disclosed is the compound (L)
13
[0025] where R is 4-(BnO)-phenyl, which falls outside the scope of the present invention.
[0026] The present invention provides aryl piperidine derivatives which are particularly useful in treating cardiovascular disorders associated with elevated levels of circulating LDL-cholesterol.
[0027] Thus, the present invention provides, as a first aspect, a compound of formula (I)
14
[0028] wherein
[0029] Ar1 represents phenyl, naphthyl or phenyl fused by a C3-8cycloalkyl, where each group is optionally substituted by methylenedioxy or one or two groups independently represented by R1;
[0030] Ar2 represents phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from halogen, C1-4 alkyl and C1-4 alkoxy;
[0031] Ar3 represents a phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from hydroxy, alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkenyloxy, C1-4 perfluoroalkoxy, C1-4 acylamino or an electron withdrawing group;
[0032] A represents —C(H)—;
[0033] E represents —C1-6 alkylene-;
[0034] X represents —CON(H or C1-4alkyl )- or —N(H or C1-4alkyl)CO—;
[0035] Y represents a direct link;
[0036] R1 represents halogen, —S(C1-4 alkyl)-, —O—(C0-4 alkylene)-R2 or —(C0-4alkylene)-R2, where each alkylene group may additionally incorporate an oxygen in the chain, with the proviso that there are at least two carbon atoms between any chain heteroatoms;
[0037] R2 represents
[0038] (i) hydrogen, C1-4 perfluoroalkyl, C2-3 alkenyl,
[0039] (ii) phenyl, naphthyl, a 5- or 6-membered heteroaromatic group or 1,2,3,4-tetrahydronaphthyl, optionally substituted by one or two halogen, hydroxy, C1-4 alkyl, C1-4 alkoxy groups,
[0040] (iii) C3-8cycloalkyl, a 3-7 membered heterocycloalkyl,
[0041] (iv) amino, C1-4 alkylamino or di-C1-4alkylamino, with the proviso that there are at least two carbon atoms between any chain heteroatoms;
[0042] or a physiologically acceptable salt or solvate thereof.
[0043] Suitable physiologically acceptable salts of the compounds of general formula (I) include acid addition salts formed with pharmaceutically acceptable inorganic acids for example, hydrochlorides, hydrobromides or sulphates, or with pharmaceutically acceptable organic acids for example mesylates, lqctqtes and acetates. More suitably, a physiologically acceptable salt of the compounds of general formula (I) is a mesylate salt.
[0044] The solvates may, for example, be hydrates.
[0045] References herein after to a compound according to the invention include both compounds of formula (I) and their physiologically acceptable salts together with physiologically acceptable solvates.
[0046] Referring to the general formula (I), alkyl, alkylene and alkoxy include both straight and branched chain saturated hydrocarbon groups. Examples of alkyl groups include methyl and ethyl groups, examples of alkylene groups include methylene and ethylene groups, whilst examples of alkoxy groups include methoxy and ethoxy groups.
[0047] Referring to the general formula (I), alkenyl includes both straight and branched chain saturated hydrocarbon groups containing one double bond. Examples of alkenyl groups include ethenyl or n-propenyl groups.
[0048] Referring to the general formula (I), acyl refers to aliphatic or cyclic hydrocarbons attached to a carbonyl group through which the substituent bonds, such as acetyl.
[0049] Referring to the general formula (I), phenyl fused by a C3-8cycloalkyl includes bicyclic rings such as 1,2,3,4-tetrahydronaphthyl, which, for the avoidance of doubt, is linked to the rest of the molecule through the aromatic ring.
[0050] Referring to general formula (I), a halogen atom includes fluorine, chlorine, bromine or iodine.
[0051] Referring to the general formula (I), C1-3perfluoroalkyl and C1-3perfluoroalkoxy includes compounds which the hydrogens have been partially or fully replaced by fluorines, such as trifluoromethyl and trifluoromethoxy or trifluoroethyl.
[0052] Referring to the general formula (I), a 5-6 membered heteroaromatic group includes a single aromatic ring system containing at least one ring heteroatom independently selected from O, N and S. Suitable examples include pyridyl and thiazolyl.
[0053] Referring to the general formula (I), a C3-8 cycloalkyl group means any single carbocyclic ring system, wherein said ring is fully or partially saturated. Suitable examples include cyclopropyl and cyclohexyl groups.
[0054] Referring to the general formula (I), a 3-7 membered heterocycloalkyl group means any single ring system containing at least one ring heteroatom independently selected from O, N and S, wherein said ring is fully or partially saturated.
[0055] Suitably, Ar1 represents an optionally substituted phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl group, where optional substitution is effected by R1. More suitably, Ar1 represents a substituted phenyl or naphthyl. Preferably Ar1 represents a substituted phenyl. Equally preferably, Ar1 represents a substituted naphthyl. Equally preferably, Ar1 represents a substituted-1,2,3,4-tetrahydronaphthyl group.
[0056] Substitution on Ar1 is suitably represented by methylenedioxy or one or two groups independently selected from hydroxy, C1-4 alkyl, e.g. methyl, ethyl or isopropyl, C1-4 alkoxy, e.g. methoxy or ethoxy, —O—C0-4alkylene-R2, e.g. —O—methylene-R2, where R2 represents C1-4 perfluoroalkyl, e.g. trifluoromethyl, a 5-6 membered heteroaromatic group, e.g. pyridyl, preferably 2-pyridyl, or a C3-8cycloalkyl, e.g. cyclopropyl.
[0057] Substitution on Ar1 is equally suitably represented by one or two groups independently selected from hydroxy, C1-4 alkyl, e.g. methyl or ethyl, C1-4 alkoxy, e.g. methoxy, ethoxy, propoxy or isobutoxy, C2-3alkenyloxy, e.g. allyloxy or —O—C0-4alkylene-R2, e.g. —O-methylene-R2, where R2 represents a C3-8cycloalkyl, e.g. cyclopropyl.
[0058] Preferably, Ar1 is a phenyl group substituted by methylenedioxy, preferably 3,4-methylenedioxy, or one or two groups independently selected from methyl, ethyl, isopropyl, hydroxy, methoxy, ethoxy, cyclopropylmethoxy and 2-pyridylmethoxy. Preferably, substitution is in one or two of the 2-, 4- or 5-positions on the phenyl ring.
[0059] Equally preferably, Ar1 is a phenyl or naphthyl group substituted by one or two groups independently selected from methyl, ethyl, hydroxy, methoxy, ethoxy, propoxy, isobutoxy, allyloxy and cyclopropylmethoxy. Preferably, where Ar1 is phenyl, substitution is in one or two of the 2- or 4-positions on the phenyl ring.
[0060] Where Ar1 is naphthyl, the link to group A is preferably through the 1- or 2-position and mono-substitution by R1 is in either the corresponding 2- or 1-positions respectively.
[0061] E is preferably an n-butylene group.
[0062] X is suitably a —N(H or C1-4 alkyl)CO— group, preferably an —N(H)CO— group.
[0063] Where Ar2 is a 5-6-membered heteroaromatic group, this is suitably a thiazolyl group, optionally substituted by C1-4 alkyl, e.g. methyl. Ar2 is preferably phenyl.
[0064] Suitable electron withdrawing groups on Ar3 include halogen, nitrile, nitro, C1-4, C1-4 perfluoroalkyl, C1-4 acyl , C1-4 alkoxycarbonyl, aminocarbonyl, C1-4 alkylaminocarbonyl; di-C1-4 alkylaminocarbonyl, C1-4 alkylsulfonyl, C1-4 alkylaminosulfonyl and di-C1-4 alkylaminosulfonyl, C1-4 alkylsulfonyl and C1-4alkylsulfoxy.
[0065] Ar3 is preferably phenyl or pyridyl group, suitably 2-pyridyl, substituted by halogen, e.g. chloro or C1-4perfluoroalkyl, e.g. trifluoromethyl.
[0066] Ar3 is equally preferably phenyl substituted by a halogen, e.g. chloro, C1-4perfluoroalkyl, e.g. trifluoromethyl, C1-4acyl, e.g. acetyl, nitrile or C1-4alkylsulfonyl, e.g. methylsulfonyl.
[0067] When Ar3 is phenyl, para-substitution is preferred.
[0068] More preferably, Ar3 is phenyl substituted by a halogen, e.g. chloro or nitrile. Most preferably, Ar3 is phenyl substituted by chloro in the para position. Alternatively, Ar3 is phenyl substituted by nitrile in the para position.
[0069] A suitable sub-group of the present invention is represented by a compound of formula (Ia)
15
[0070] wherein
[0071] Ar1 represents phenyl, naphthyl or phenyl fused by a C3-8cycloalkyl, where each group is optionally substituted by methylenedioxy or one or two groups independently represented by R1;
[0072] Ar2 represents phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from halogen, C1-4 alkyl and C1-4 alkoxy;
[0073] Ar3 represents phenyl or a 5-6 membered heteroaromatic group, where each group is optionally substituted by one to four groups independently selected from halogen, hydroxy, nitrile, C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkenyloxy, C1-4 perfluoroalkyl, C1-4 perfluoroalkoxy, C1-4 acyl, C1-4 alkoxycarbonyl, aminocarbonyl, C1-4 alkylaminocarbonyl; di-C1-4 alkylaminocarbonyl and C1-4 acylamino;
[0074] A represents —C(H)—;
[0075] E represents —C1-6 alkylene-;
[0076] X represents —CON(H or C1-4alkyl )- or —N(H or C1-4alkyl)CO—;
[0077] Y represents a direct link;
[0078] R1 represents halogen, —O—(C0-4 alkylene)-R2 or —C0-4alkylene)-R2, where each alkylene group may additionally incorporate an oxygen in the chain, with the proviso that there are at least two carbon atoms between any chain heteroatoms;
[0079] R2 represents
[0080] (i) hydrogen, C1-4 perfluoroalkyl,
[0081] (ii) phenyl, naphthyl, a 5- or 6-membered heteroaromatic group or 1,2,3,4-tetrahydronaphthyl, optionally substituted by one or two halogen, hydroxy, C1-4 alkyl, C1-4 alkoxy groups,
[0082] (iii) C3-8cycloalkyl, a 3-7 membered heterocycloalkyl,
[0083] (iv) amino, C1-4 alkylamino or di-C1-4alkylamino, with the proviso that there are at least two carbon atoms between any chain heteroatoms;
[0084] or a physiologically acceptable salt or solvate thereof.
[0085] A further preferred sub-group of the present invention is represented by a compound of formula (Ib)
16
[0086] wherein
[0087] Ar1 represents phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl, where each group is optionally substituted by one or two groups independently represented by R1;
[0088] Ar3 represents phenyl substituted in the para position by a halogen, nitrile, C1-4acyl, C1-4alkylsulfonyl or C1-4 perfluoroalkyl group;
[0089] R1 represents C1-4 alkyl or —O—(C0-4alkylene)-R2;
[0090] R2 represents hydrogen, C2-3alkenyl or C3-8cycloalkyl;
[0091] or a physiologically acceptable salt or solvate thereof.
[0092] It will be understood that references to compounds of formula (I) hereinbefore and hereinafter apply equally to compounds of formula (Ia) and (Ib).
[0093] Particularly preferred compounds of the invention include those in which each variable in Formula (I) is selected from the preferred groups for each variable. Even more preferable compounds of the invention include those where each variable in Formula (I) is selected from the more preferred or most preferred groups for each variable.
[0094] Suitable compounds according to the invention include:
[0095] 4′-Trifluoromethyl-biphenyl-4-carboxylic acid {4-[4-(2-ethoxy-4-methyl-phenyl)-piperidin-1-yl]-butyl}-amide;
[0096] 4′-Trifluoromethyl-biphenyl-4-carboxylic acid [4-[4-(2-cyclopropylmethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl]-amide;
[0097] 4′-Chloro-biphenyl-4-carboxylic acid {4-[4-(1-methoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide;
[0098] 4′-Chloro-biphenyl-4-carboxylic acid {4-[4-(2-methoxy-naphtalen-1-yl)-piperidin-1-yl]-butyl}-amide;
[0099] 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(2-ethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-amide;
[0100] 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(1-methoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide;
[0101] 4′Trifluoromethyl-biphenyl-4-carboxylic acid {4-[4-(1-isobutoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0102] 4′-Trifluoromethyl-biphenyl-4-carboxylic acid {4-[4-(1-allyloxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide;
[0103] 4′-Trifluoromethyl-biphenyl-4-carboxylic acid {4-[4-(1-propoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide;
[0104] 4′-Trifluoromethyl-biphenyl-4-carboxylic acid {4-[4-(1-Cyclopropylmethoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide;
[0105] 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(1-methoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide;
[0106] 4′-Methanesulfonyl-biphenylcarboxylic acid {4-[4-(2-ethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-amide;
[0107] 4-Methyl-2-(4-trifluromethyl-phenyl)-thiazole-5-carboxylic acid {4-[4-(4-isopropyl-2-methoxy-phenyl)-piperidin-1-yl]-butyl}-amide;
[0108] 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(2-hydroxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-amide;
[0109] 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(1-hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide;
[0110] 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(1-hydroxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide;
[0111] 4′-Acetyl-biphenyl-4-carboxylic acid {4-[4-(1-hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide;
[0112] 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(2-hydroxy-4-methyl-phenyl)-piperidin-1-yl]-butyl}-amide;
[0113] or a physiologically acceptable salt or solvate thereof.
[0114] The compounds of the invention are inducers of LDL-r expression and are thus of use in the treatment of conditions resulting from elevated circulating levels of LDL-cholesterol.
[0115] The ability of the compounds of the invention to induce LDL-r expression by human hepatocytes in vitro is determined using a human hepatocarcinoma cell line, Hep G2, as a model system. A reporter gene assay using the LDL-r promoter in front of the reporter gene Luciferase is used as a primary screen.
[0116] The in vivo profile of the compounds is evaluated by oral administration of the compounds of the invention to fat-fed hamsters. Measurements of VLD/LDL cholesterol and triglycerides upon treatment allow the activity to be determined.
[0117] The compounds of the invention are potent and specific inducers of LDL-r expression, which furthermore exhibit good oral bioavailability and duration of action.
[0118] Compounds of the invention are of use in the treatment of diseases in which lipid imbalance is important, e.g. atherosclerosis, pancreatitis, non-insulin dependent diabetes mellitus (NIDDM), coronary heart diseases and obesity.
[0119] Compounds of the invention are also useful in lowering serum lipid levels, cholesterol and/or triglycerides, and are of use in the treatment of hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia.
[0120] The invention therefore provides a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use in therapy, in particular in human medicine.
[0121] There is also provided as a further aspect of the invention the use of a compound of formula (I) or a physiologically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions resulting from elevated circulating levels of LDL-cholesterol.
[0122] In an alternative or further aspect there is provided a method for the treatment of a mammal, including man, in particular in the treatment of conditions resulting from elevated circulating levels of LDL-cholesterol, comprising administration of an effective amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof.
[0123] It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms. Compounds of formula (I) may be administered as the raw chemical but the active ingredient is preferably presented as a pharmaceutical formulation.
[0124] Accordingly, the invention also provides a pharmaceutical composition which comprises at least one compound of formula (I) or a physiologically acceptable salt or solvate thereof and formulated for administration by any convenient route. Such compositions are preferably in a form adapted for use in medicine, in particular human medicine, and can conveniently be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients.
[0125] Thus compounds of formula (I) may be formulated for oral, buccal, parenteral, transdermal, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
[0126] For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
[0127] Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
[0128] For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.
[0129] For transdermal administration the compounds according to the invention may be formulated as creams, gels, ointments or lotions or as a transdermal patch. Such compositions may for example be formulated with an aqueous or oily base with the addition of suitable thickening, gelling, emulsifying, stabilising, dispersing, suspending, and/or colouring agents.
[0130] The compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
[0131] The compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
[0132] Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
[0133] The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
[0134] The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
[0135] For intranasal administration, the compounds of the invention may be formulated as solutions for administration via a suitable metered or unit dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.
[0136] The compositions may contain from 0.1% upwards, e.g. 0.1-99% of the active material, depending on the method of administration. A proposed dose of the compounds of the invention is 0.25 mg/kg to about 125 mg/kg bodyweight per day e.g. 20 mg/kg to 100 mg/kg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also depend on the route of administration and the particular compound selected.
[0137] The compounds of formula (I) may, if desired, be administered with one or more therapeutic agents and formulated for administration by any convenient route in a conventional manner. Appropriate doses will be readily appreciated by those skilled in the art. For example, the compounds of formula (I) may be administered in combination with an HMG CoA reductase inhibitor, an agent for inhibition of bile acid transport or fibrates.
[0138] A compound of formula (I), or a physiologically acceptable salt, solvate or derivative thereof, may be prepared by the general methods outlined hereafter. In the following description, the groups Ar1, Ar2, Ar3, R1, R2, A, E and X are as previously defined for compounds of formula (I), unless specified otherwise.
[0139] According to a first general process (A), a compound of formula (I) may be prepared by reaction of a compound of formula (II) with a compound of formula III
17
[0140] where Xa and Xb are suitable reactants to form a group X. For example, where X is N(H or C1-4 alkyl)CO, Xa is NH2 or NH(C1-4 alkyl) and Xb is COL where L is OH or a suitable leaving group, such as halide. Such a reaction may be effected under standard amide bond-forming conditions, including those described herein.
[0141] A compound of formula (II) where Xa is NH2 or NH(C1-4 alkyl), may be prepared by reaction of a compound of formula (IV) with a compound of formula (V)
18
[0142] where R5 represents H or C1-4alkyl, L′ is a suitable group, such as halide, and P is any suitable N-protecting group, under standard alkylation conditions, including those described herein, followed by removal of the protecting group under standard conditions.
[0143] A compound of formula (II) where Xa is NH2 or NH(C1-4 alkyl), may further be prepared by reaction of a compound of formula (IV) with a compound of formula (Va)
19
[0144] where R5 represents H or C1-4alkyl, where E−C1 (‘E minus C1’) means that the chain length of group E is one carbon less than that in the resulting compound (II), and P is any suitable N-protecting group, under standard reductive amination conditions, including those described herein, followed by removal of the protecting group under standard conditions.
[0145] A compound of formula (IV), where A is CH, may be prepared by reaction of a compound Ar1-sal, where sal represents the lithium or magnesium ion of Ar1, with a compound of formula (VI)
20
[0146] where P′ represents a suitable N-protecting group, such as acetyl, benzyl or benzyl-4-oxo-1 carboxylate, followed by the steps of dehydration, reduction of the resulting double bond, and finally, removal of the protecting group P′. Such chemistry has been described, for example, in European Patent Application no. 0630887.
[0147] Alternatively, a compound of formula (IV) where Ar1 is substituted by an activated ortho or para activating group for the reaction centre, Act, e.g. methoxy or hydroxy and A is CH, may be prepared by reaction of a compound of formula Ar1-Act, with a compound of formula (VI) under suitable reaction conditions such as e.g. trifluoroborane or acetic acid and aqueous hydrochloric acid, to form a tetrahydropyridyl ring, followed by reduction, e.g. under hydrogenation conditions, of the resulting double bond and finally deprotection of the N-protecting group, P′ under standard conditions.
[0148] Alternatively, a compound of formula (IV) where where Ar1 is substituted by an activated ortho or para activating group for the reaction centre, Act, e.g. methoxy or hydroxy and A is CH, may be prepared by reaction of a compound of formula Ar1-Act, with a compound of formula (VII)
21
[0149] under suitable reaction conditions such as e.g. acetic acid and aqueous hydrochloric acid to form a tetrahydropyridyl ring, followed by suitable N-protection, then reduction, e.g. under hydrogenation conditions, of the resulting double bond and finally deprotection of the N-protecting group.
[0150] A compound of formula (III) may be prepared by standard methods including, where Xb is CO2H, deprotection of a compound of formula (X)
22
[0151] where R is a suitable carboxylic acid protecting group, such as methyl.
[0152] A compound of formula (X) where R is H or a suitable protecting group and Y is a direct link, may be prepared by reaction of a compound of formula (XI), with a compound of formula (XII)
23
[0153] where bor1 represents a boronic acid group or a halide, e.g. bromide or iodide, and bor2 represents a suitable boronic acid group or a halide, e.g. bromide or iodide for coupling, under conditions suitable for boronic acid coupling, e.g. using palladium (0) and sodium carbonate.
[0154] According to a second general process (B), a compound of formula (I) may be prepared by reaction of a compound of formula (IV) with a compound of formula (XIII)
24
[0155] where E−C1 (‘E minus C1’) means that the chain length of group E is one carbon less than that in the resulting compound (I), under standard reductive amination conditions, e.g. sodium triacetoxyborohydride and acetic acid in a suitable solvent, such as dichloromethane.
[0156] A compound of formula (XIII) may be prepared by reaction of a compound of formula (XIV) with a compound of formula (XV)
25
[0157] where R15 is a suitable alkyl protecting group for oxygen, such as methyl, and Xa and Xb are suitable reactants to form a group X, as defined hereinbefore, followed by removal of the protecting group, under acidic conditions.
[0158] According to a third general process (C), a compound of formula (I) may be prepared by reaction of a different compound of formula (I), by well known methods. For example a compound of formula (I) where Ar1 is substituted by C1-4 alkoxy may be prepared from the corresponding compound of formula (I) where the substituent is hydroxy by standard O-alkylation methods.
[0159] Compounds of formula (V), (VI), (VII), (VIII), (IX), (XI), (XIV) and (XV), are known or may be prepared by standard methods, e.g. as substantially described herein.
[0160] The protecting groups used in the preparation of compounds of formula (I) may be used in conventional manner. See for example ‘Protective Groups in Organic Chemistry’ Ed. J. F. W. McOmie (Plenum Press 1973) or ‘Protective Groups in Organic Synthesis’ by Theodora W Greene and P M G Wuts. (John Wiley and Sons 1991).
[0161] Conventional amino protecting groups may include for example aralkyl groups, such as benzyl, diphenylmethyl or triphenylmethyl groups; and acyl groups such as N-benzyloxycarbonyl or t-butoxycarbonyl.
[0162] Conventional carboxylic acid protecting groups include methyl and ethyl groups.
[0163] The invention is further described with reference to the following non-limiting examples.
[0164] Abbreviations:
[0165] THF—Tetrahydrofuran, BF3-Et2O—Boron trifluoride diethyl etherate, DCM—Dichloromethane, TEA—triethylamine, EtOH—Ethanol, EtOAc—Ethyl acetate, IPr2O—Di-isopropyl ether, TFA—Trifluoroacetic acid, Pd/C—Palladium on carbon, Et2O—diethyl ether, IPrOH—Isopropanol, IprNH2—Isopropylamine, Chex—cyclohexane, MeOH—Methanol, DMF—Dimethyl formamide, EDCl—1-(3-dimethylaminopropyl)-, ethylcarbodiimide hydrochloride, HOBt—1-Hydroxybenzotriazole, MeCN—Acetonitrile, rt—Room temperature, CDl—Carbonyle diimidazole, nBuOH—nButanol, AcOH—Acetic acid CH3SO3H—Methane sulfonic acid, MgSO4—Magnesium sulfate, Na2SO4—Sodium sulfate, HATU—O-(7-Azabenzotriazol-1-yl)-N,N,N′N′-hetramethyluroniumhexafluorophosphate
4′-Trifluoromethyl-biphenyl-4-carboxylic Acid
[0166] To a solution of 4Bromo-benzoic acid (28.5 g, 0.14 mol) in toluene (350 mL) were added Tetrakis(triphenylphosphine)palladium(0) (4.93 g, 0.03 eq.), a 2M solution of Na2CO3 (71 mL), Lithium chloride (18.3 g, 3 eq.). Then a solution of 4-Trifluoromethylbenzeneboronic acid (30.0 g, 0.158 mol) in EtOH (200 mL) was added and the resulting mixture was stirred at reflux for 16 hours. After evaporation under reduced pressure the residue was taken up in water and the precipitate was filtered off. The solid was treated with a 1N HCl solution, filtered off and dried and was dissolved in a solution of EtOH (700 mL) and THF (400 mL). Filtration through a bed of silica and evaporation gave the title compound (25.0 g, 0.094 mol) as a white solid.
[0167] GC/MS: M+C14H9F3O2 266
4′-Chloro-biphenyl-4-carboxylic Acid
[0168] To a solution of 20 g (0.1 mol.) of 4-bromo benzoic acid in toluene (300 mL) was added successively 3.5 g (0.03 eq.) of tetrakis (triphenylphosphine) palladium (0), 50 ml (1 eq.) of a 2M solution of Na2CO3 and 12.9 g (3 eq.) of lithium chloride. After 15 minutes of stirring was added a solution of 10.8 g (1.2 eq.) of 4-chlorophenyl boronic acid in EtOH (120 mL). Then, the mixture was refluxed for 24 hours. After cooling, the solvents were evaporated to dryness. The residue was poured in water (300 mL) and the aqueous layer was acidified to pH=1 with a 1N HCl solution. After filtration, the solid was washed with water and after recrystallization from 2-methoxy ethanol 15 g of the tilte compound as a white powder in a 65% yield.
[0169] MP: 290-291° C.
1-[4-(2-Hydroxy-4-methyl-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-ethanone
[0170] To a solution of m-Cresol (50.0 g, 0.46 mol) and 1-Acetyl-4-piperidone (65.4 g, 1.0 eq.) was added dropwise BF3-Et2O (176 mL, 3.0 eq). The mixture was stirred at 100° C. for 2 hours. After cooling to rt, the mixture was treated with a 1N HCl solution (800 mL). The resulting solution was extracted with DCM. The organic layer was dried over Na2SO4 and evaporated to dryness to give an oil which was crytallized in MeCN to give the title compound (60.0 g, 0.26 mol) as a white powder in a 57%.
[0171] GC/MS: M+C14H17NO2 231
1-[4-(2-Hydroxy-4-methyl-phenyl)-piperidin-1-yl]-ethanone.
[0172] To a solution of intermediate 3 (60.0 g, 0.26 mol) in EtOH (600 mL) and DCM (200 mL) was added Pd/C, 10% (6 g) and the reaction was stirred under an atmospheric pressure of hydrogen at rt for 48 hours. The reaction mixture was filtered through a bed of celite. The filtrate was evaporated under reduced pressure to give the title compound (55.0 g, 0.24 mol) as a white powder.
[0173] GC/MS: M+C14H19NO2 233
1-[4-(2-Ethoxy-4-methyl-phenyl)-piperidin-1-yl]-ethanone
[0174] To a solution of intermediate 4 (55.0 g, 0.24 mol) in dry acetone (800 mL) was added anhydrous Cs2CO3 (93.0 g, 1.2 eq.) and ethyl iodide (23 mL, 1.2 eq.). The reaction was stirred under reflux for 18 hours. After cooling, the reaction was filtered off and washed with acetone. The filtrate was evaporated under reduced pressure to give the title compound as an oil (53.0 g, 0.20 mol).
[0175] GC/MS: M+C16H23NO2 261
4-(2-Ethoxy-4-methyl-phenyl)-piperidine
[0176] To a solution of intermediate 5 (53.0 g, 0.20 mol) in MeOH (600 mL) was added a solution of NaOH (260 mL) in H2O (260 mL). The reaction was stirred under reflux for 48 hours. After cooling, the reaction was concentrated under reduced pressure, was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give the title compound (40.0 g, 0.18 mol) as a yellow oil.
[0177] GC/MS: M+C14H21NO 219
2-{4-[4-(2-Ethoxy-4-methyl-phenyl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0178] A solution of intermediate 6 (39.5 g, 0.18 mol) in acetone (600 mL) was treated with Cs2CO3 (64.5 g, 1.1 eq.) and N-(4-Bromobutyl)-phtalimide (50.9 g, 1.0 eq.). The resulting mixture was stirred under reflux for 24 hours. After cooling to rt the reaction mixture was filtered off. The cake was washed with acetone. The filtrate was evaporated off to give the title compound (60.0 g, 0.14 mol) as a yellow oil.
[0179] GC/MS: M+C26H32N2O3 420
4-[4-(2-Ethoxy-4-methyl-phenyl)-piperidin-1-yl]-butylamine
[0180] A solution of intermediate 7 (60.0 g, 0.14 mol) in MeOH (600 mL) was treated with hydrazine hydrate (28 mL). The resulting mixture was stirred at 60° C. for 3 hours. After evaporation under reduced pressure the residue was taken up in water and treated with a concentrated HCl solution until PH=3. The white precipitate was filtered off, washed with water and the filtrate was treated with a concentrated NaOH solution until PH=13. Extraction with DCM, drying over Na2SO4 and filtration gave the title compound (37.0 g, 0.13 mol) as a yellow oil.
[0181] GC/MS: M+C18H30N2O 290
1-[4-(4-Ethyl-2-hydroxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-ethanone
[0182] The same method was employed as in the preparation of intermediate 3 but starting from the 3-Ethyl-phenol gave the title compound as a pink solid in a quantitative yield.
[0183] GC/MS: M+C15H19NO2 245
1-[4-(4-Ethyl-2-Hydroxy-phenyl)-piperidin-1-yl]-ethanone
[0184] The same method was employed as in the preparation of intermediate 4 but starting from the intermediate 9 gave the title compound as a solid in a 89% yield.
[0185] GC/MS: M+C15H21NO2 247
1-[4-(2-Cyclopropylmethoxy-4-ethyl-phenyl)-piperidin-1-yl]-ethanone
[0186] To a solution of 7.6 g of the intermediate 10 in acetone (200 mL) was added Cs2CO3 (12.1 g, 37 mmol ) and bromo-methylcyclopropane (5 g, 37 mmol) The mixture was then stirred at 50° C. during 24 hours. After cooling, the mixture was filtrated off and the white cake was washed with DCM. The filtrate was evaporated under vacuo to give 8.6 g of the title compound as a yellow residue in a 92% yield.
[0187] GC/MS: M+C19H27NO2 301
4-(2-cyclopropylmethoxy-4-ethyl-phenyl)-piperidine
[0188] To a solution of 8.5 g (28.2 mmol) of the intermediate 11 in MeOH (75 mL) was added dropwise a 1/1 solution of 35% NaOH (37 mL) and H2O (37 mL). The resulting mixture was stirred at 70° C. during 6 hours. After cooling to rt and evaporation under reduced pressure, the residue was taken up in AcOEt and washed with brine. The organic phase was separated, dried over Na2SO4 and evaporated off to afford 5.65 g of the title compound as a yellow oil in a 77% yield.
[0189] GC/MS: M+C17H25NO 259
2-[4-[4-(2-Cyclopropylmethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl]-isoindole-1,3-dione
[0190] The same method was employed as in the preparation of intermediate 7 but starting from the intermediate 12 gave the title compound as a yellow oil in a 55% yield.
[0191] LC/MS (APCI): [M+H+]461 C29H36N2O3
4-[4-(2-Cyclopropylmethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butylamine
[0192] The same method was employed as in the preparation of intermediate 8 but starting from the intermediate 13 gave the title compound as a yellow oil in a 97% yield.
[0193] LC/MS (APCI): [M+H+] 331 C21H34N2O
1-[4-(1-Hydroxy-naphtalen-2-yl)-3,6-dihydro-2H-pyridin-1-yl]-ethanone
[0194] The same method was employed as in the preparation of intermediate 3 but starting from the 1-Naphtol gave the title compound as a white solid in a 54% yield.
[0195] GC/MS: M+C17H17NO2 267
1-[4(1-Hydroxy-naphtalen-2-yl)-piperidin-1-yl]-ethanone
[0196] A solution of intermediate 15 (29.0 g, 0.112 mol) in a mixture of cyclohexene (450 mL), MeOH (100 mL), THF (350 mL) was treated with Pd(OH)2, 50% (14 g). The resulting solution was allowed to stir at reflux for 4 days. After cooling, the reaction mixture was filtered through a bed of celite. The filtrate was evaporated to dryness to give the title compound as a white solid (22.0 g, 0.082 mol) in a 73% yield after recrystallization from CH3CN.
[0197] LC/MS: [M+H+] C17H19NO2 270
1-[4-(1-Methoxy-naphtalen-2-yl)-piperidin-1-yl]-ethanone
[0198] To a solution of intermediate 16 (22.0 g, 0.08 mol) in dry DMF (400 mL) was added K2CO3 (23.0 g, 2 eq.) and methyl iodide (20.4 mL, 4 eq.). The reaction was stirred at 80° C. for 16 hours. After cooling, the reaction was filtered off and evaporated under reduced pressure. The oil was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give the title compound as a white solid in a quantitative yield.
[0199] GC/MS: M+C18H12NO2 283
4-(1-Methoxy-naphtalen-2-yl)-piperidine
[0200] To a solution of the intermediate 17 (23.0 g, 82 mmol) in EtOH (400 mL) was added dropwise a 1/1 solution of a concentrated NaOH solution and H2O (100 mL). The resulting mixture was stirred at 100° C. during 16 hours. After cooling to rt and evaporation under reduced pressure, the residue was taken up in DCM and washed with water. The organic phase was dried over Na2SO4 and evaporated off to give the title compound as an oil (10.6 g, 44 mmol).
[0201] GC/MS: M+C16H19NO 241
[0202]
2
-{4-[4-(1-Methoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0203] The same method was employed as in the preparation of intermediate 7 but starting from intermediate 18 gave the title compound as a oil in a 88% yield.
[0204] LC/MS (APCI): [M+H+]443 C28H30N2O3
4-[4-(1-Methoxy-naphtalen-2-yl)-piperidin-1-yl]-butylamine
[0205] The same method was employed as in the preparation of intermediate 8 but starting from intermediate 19 gave the title compound as a yellow oil in a 97% yield.
[0206] LC/MS (APCI): [M+H+]313 C20H28N2O
1-Bromo-2-methoxy-naphtalene
[0207] To a solution of 1-Bromo-naphtalen-2-ol (20.0 g, 0.089 mol) in acetone (300 mL) was added K2CO3 (25.0 g, 2 eq.) and methyl iodide (16.75 mL, 3 eq.). The reaction was stirred at reflux for 3 hours. After cooling, the reaction was filtered off and evaporated under reduced pressure. The oil was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give the title compound as a colorless solid in a quantitative yield.
[0208] GC/MS: M+C11H9BrO 237
4-Hydroxy-4-(2-methoxy-naphtalen-1-yl)-piperidine-1-carboxylic acid ter-butyl Ester
[0209] A solution of intermediate 21 (10.0 g, 0.042 mol) in THF (100 mL) was cooled to −78° C. and treated with nBuLi (2.0 M in cyclohexane, 21 mL, 1.0 eq.). The resulting mixture was stirred for 2 hours at −55° C. At −78° C. a solution of the 1-Boc4-piperidone (8.40 g, 1 eq.) in THF (30 mL) was added. The resulting mixture was allowed to stir at rt ° C. for 3 hours. Addition of a saturated ammonium chloride solution, extraction with Et2O, drying over Na2SO4 and evaporation under reduced pressure gave the title compound (6.88 g, 0.019 mol) as an oil after purification by flash chromatography (DCM as eluent) in a 46% yield.
[0210] GC/MS: M+C21H27NO4 357
4-(2-Methoxy-naphtalen-1-yl)-piperidine
[0211] A solution of intermediate 22 (6.88 g, 0.019 mol) in DCM (100 mL) was treated with TFA (14.6 mL, 10 eq.) and triethyl silane (61 mL, 20 eq.) at rt. The resulting solution was allowed to stir at rt for 24 hours. The solvent was evaporated under reduced pressure. The residue was diluted in DCM and washed with a 1N NaOH solution, dried over Na2SO4 and evaporated off to give the title compound (3.9 g, 0.016 mol) as an oil in a 84% yield. The crude compound was used in the next step without purification.
2-{4-[4-(2-Methoxy-naphtalen-1-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0212] The same method was employed as in the preparation of intermediate 7 but starting from intermediate 23 gave the title compound as a yellow oil in a 54% yield.
[0213] LC/MS (APCI): [M+H+]443 C28H30N2O3
4-[4-(2-Methoxy-naphtalen-1-yl)-piperidin-1-yl]-butylamine
[0214] The same method was employed as in the preparation of intermediate 8 but starting from intermediate 24 gave the title compound as a yellow oil in a 76% yield.
[0215] GC/MS: M+C20H28N2O 312
5-Ethyl-2-(1,2,3,6-tetrahydro-pyridin-4-yl)-phenol
[0216] A solution of 3-Ethyl-phenol (122.2 g, 1.0 mol) and 4-Piperidone hydrate hydrochloride (183.0 g, 1.2 eq.) in acetic acid (500 mL) was treated with HCl gaz for 10 min. The mixture was stirred at 95° C. for 30 min. After cooling to rt, the mixture was treated again with HCl gaz for 10 min. The resulting solution was allowed to stir at rt for 4 days. The solvent was evaporated under reduced pressure to give a colorless oil (200.0 g). The product was used without further purification.
Acetic Acid 2-(1-acetyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-ethyl-phenyl Ester
[0217] To a solution of intermediate 26 (33.0 g, 0.162 mol) in pyridine (300 mL) was added acetic anhydride (100 mL). The mixture was stirred at rt for 4 hours. The solvents were evaporated under reduce pressure. The oil was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give the title compound (28.0 g, 0.097 mol) as a yellow oil in a 60% yield.
[0218] 1H NMR (CDCl3, 250 MHz) δ 7 (m, 2H), 6.7 (m, 1H), 5.65 (m, 1H), 4.05 (m, 2H), 3.55 (dt, 2H), 2.6 (q, 2H), 2.3 (m, 2H), 2.15 (s, 3H), 2.05 (d, 3H), 1.1 (t, 3H).
1-[4-(4-Ethyl-2-hydroxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-ethanone
[0219] To a solution of intermediate 27 (28.0 g, 0.098 mol) in MeOH (700 mL) was added K2CO3 (40.0 g, 3 eq.) and the mixture was stirred under reflux for 4 hours. The solution was filtered off and the methanol was evaporated. The oil was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give the title compound (20.0 g, 0.082 mol) as an orange oil in a 84% yield.
[0220] 1H NMR (CDCl3, 250 MHz) δ 6.7 (m, 2H), 6.6 (m, 1H), 5.8 (m, 1H), 4.1 (m, 2H), 3.65 (m, 2H), 2.7 (m, 5H), 2.4 (q, 2H),1.2 (t, 3H).
1-[4-(4-Ethyl-2-hydroxy-phenyl)-piperidin-1-yl]-ethanone
[0221] To a solution of intermediate 28 (20.0 g, 0.082 mol) in MeOH (600 mL) was added Pd/C, 10% (1.2 g) and the reaction was stirred under an atmospheric pressure of hydrogen for 16 hours. The reaction mixture was filtered through a bed of celite. The filtrate was evaporated under reduced pressure to give the title compound (15.0 g, 0.06 mol) as an oil in a 75% yield.
[0222] 1H NMR (CDCl3, 250 MHz) δ 6.85 (d, 1H), 6.6 (m, 2H), 4.65 (m, 1H), 3.8 (m, 1H), 3.2-2.9 (m, 2H), 2.6 (m, 1H), 2.45 (q, 2H), 2.05 (s, 3H), 1.7 (m, 2H), 1.5 (m, 2H), 1.1 (t, 3H).
1-[4-(2-Ethoxy-4-ethyl-phenyl)-piperidin-1-yl]-ethanone
[0223] To a solution of intermediate 29 (7.41 g, 0.03 mol) in dry acetone (150 mL) was added anhydrous Cs2CO3 (14.7 g, 1.5 eq.) and ethyl iodide (4.8 mL, 2 eq.). The reaction was stirred under reflux for 5 hours. After cooling, the reaction was filtered off and washed with acetone. The filtrate was evaporated under reduced pressure to give the title compound as an oil (8.2 g, 0.03 mol) in a quantitative yield.
[0224] 1H NMR (CDCl3, 250 MHz) δ 6.9 (d, 1H), 6.6 (m, 2H), 4.7 (m, 1H), 4.0 (q, 2H) 3.8 (m, 1H), 3.1 (m, 2H), 2.5 (m, 3H), 2.05 (s, 3H), 1.7 (m, 2H), 1.5 (m, 2H), 1.35 (t, 3H), 1.1 (t, 3H).
4-(2-Ethoxy-4-ethyl-phenyl)-piperidine
[0225] To a solution of intermediate 30 (8.17 g, 0.03 mol) in MeOH (150 mL) was added a solution of NaOH (37 mL) in H2O (37 mL). The reaction was stirred under reflux for 12 hours. After cooling, the reaction was concentrated under reduced pressure, was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give the title compound (6.6 g, 0.028 mol) as a yellow oil in a 94% yield.
[0226] 1H NMR (CDCl3, 250 MHz) δ 7.1 (d, 1H), 6.7 (d, 1H), 4.7 (d, 1H), 4.05 (q, 2H) 3.1 (m, 2H), 3.05 (m, 1H), 2.7 (td, 2H), 2.55 (q, 2H), 1.75 (m, 3H), 1.55 (m, 2H), 1.35 (t, 3H), 1.1 (t, 3H).
2-{4-[4-(2-Ethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0227] The same method was employed as in the preparation of intermediate 7 but starting from intermediate 31 gave the title compound as a yellow oil in a 97% yield.
[0228] 1H NMR (CDCl3, 250 MHz) δ 7.8 (m, 2H), 7.6 (m, 2H), 7.0 (d, 1H), 6.65 (dd, 1H), 6.55 (sd, 1H), 3.95 (q, 2H), 3.65 (m, 3H), 2.95 (m, 2H), 2.8 (m, 1H), 2.5 (q, 2H), 2.4 (m, 2H), 2 (td, 2H), 1.8-1.4 m, 8H), 1.3 (t, 3H), 1.15 (t, 3H).
4-[4-(2-Ethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butylamine
[0229] The same method was employed as in the preparation of intermediate 8 but starting from intermediate 32 gave the title compound as a yellow oil in a 81.5% yield.
[0230] 1H NMR (CDCl3, 250 MHz) δ 7.1 (d, 1H), 6.7 (dd, 1H), 6.6 (s, 1H), 4.0 (q, 2H), 3.0 (bd, 2H), 2.9 (m, 1H), 2.7 (t, 2H), 2.55 (q, 2H), 2.3 (m, 2H), 2.0 (td, 2H), 1.7-1.2 (m, 10H), 1.4 (t, 3H), 1.1 (t, 3H).
1-[4-(1-Hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-3,6-dihydro-2H-pyridin-1-yl]-ethanone
[0231] The same method was employed as in the preparation of intermediate 3 but starting from the 5,6,7,8-tetrahydro-1-naphtol to give the title compound as a powder after crystallization in CH3CN in a 100% yield.
[0232] GC/MS: M+C17H21NO2 271
1-[4-(1-Hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-ethanone
[0233] To a solution of intermediate 34 (55.0 g, 0.203 mol) in AcOH (500 mL) was added Pd/C, 10% (2 g) and the reaction was stirred under an atmospheric pressure of hydrogen at 50° C. for 24 hours. The mixture was filtered through a bed of celite. The filtrate was evaporated under reduced pressure to give the title compound (55.0 g, 0.201 mol) as a yellow powder.
[0234] GC/MS: M+C17H22NO2 273
1-[4-(1-Isobutoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-ethanone
[0235] To a solution of Intermediate 35 (10.0 g, 0.037 mol) in dry acetone (200 mL) was added K2CO3 (15.2 g, 3 eq.) and 1-Bromo-2-methylpropane (5.2 mL, 1.3 eq.). The reaction was stirred under reflux for 24 hours. After cooling, the reaction was filtered off and washed with acetone. The filtrate was evaporated under reduced pressure to give the title compound as an oil (7.0 g, 0.021 mol).
[0236] GC/MS: M+C21H31NO2 329
4-(1-Isobutoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidine
[0237] The same method was employed as in the preparation of intermediate 12 but starting from the intermediate 36 to give the title compound as a yellow oil in a 100% yield.
[0238] GC/MS: M+C19H29NO 287
2-{4-[4-(1-Isobutoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0239] The same method was employed as in the preparation of intermediate 7 but starting from the intermediate 37 to give the title compound as a colorless oil in a 73.5% yield.
[0240] LC/MS (APCI): [M+H+] C31H40N2O3 489
4-[4-(1-Isobutoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butylamine
[0241] The same method was employed as in the preparation of intermediate 8 but starting from the intermediate 38 to give the title compound as a yellow oil in a 69% yield.
[0242] GC/MS: M+C23H38N2O 358
1-[4-(1-Allyloxy-naphtalen-2-yl)-piperidin-1-yl]-ethanone
[0243] A solution of intermediate 35 (6.0 g, 0.022 mol) in acetone (300 mL) was treated with Cs2CO3 (14.3 g, 2 eq.) and allyl bromide (2.2 mL, 1.1 eq.). The resulting mixture was stirred at reflux for 4 hours and filtrated off after cooling to rt. The filtrate was evaporated off and addition of water, extraction with DCM, drying over Na2SO4 and evaporation under reduced pressure gave the title compound (4.5 g, 0.015 mol) as beige solid, which was crystallised from iPr2O in a 67% yield.
[0244]
1
H NMR (CDCl3, 300 MHz) δ 7.9 (d, 1H), 7.6 (d, 1H), 7.45 (d, 1H), 7.3 (m, 2H), 7.1 (d, 1H), 6.0 (m, 1H), 5.4 (d, 1H), 5.2 (d, 1H), 4.65 (d, 1H), 4.35 (dd, 2H), 3.8 (d, 1H), 3.5 (m, 1H), 3.0 (t, 1H), 2.5 (t, 1H), 2.0 (s, 3H), 1.6 (m, 4H).
4-(1-Allyloxy-naphtalen-2-yl)-piperidine
[0245] The same method was employed as in the preparation of intermediate 12 but starting from the intermediate 40 to give the title compound as a pink oil in a quantitative yield.
[0246]
1
H NMR (CDCl3, 300 MHz) δ 8.0 (d, 1H), 7.8 (d, 1H), 7.5 (d, 1H), 7.3 (m, 3H), 6.2 (m, 1H), 5.4 (d, 1H), 5.2 (d, 1H), 4.4 (d, 1H), 3.6 (m, 1H), 3.2 (m, 1H), 3.0 (m, 2H), 2.7 (m, 2H), 1.6 (m, 4H).
2-{4-[4-(1-Allyloxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0247] The same method was employed as in the preparation of intermediate 7 but starting from intermediate 41 gave the title compound as pink crystals (3.7 g, 7.9 mmol) in a 50% yield.
[0248]
1
H NMR (CDCl3, 300 MHz) δ 8.1 (d, 1H), 7.9 (m, 3H), 7.8 (m, 2H), 7.6 (d, 1H), 7.3 (m, 3H), 6.2 (m, 1H), 5.5 (d, 1H), 5.3 (d, 1H), 4.4 (d, 2H), 3.8 (t, 2H), 3.3 (m, 1H), 3.0 (d, 2H), 2.4 (t, 2H), 2.1 (t, 2H), 2.0 (m, 2H), 1.7 (m, 4H), 1.6 (m, 2H).
4-[4-(1-Allyloxy-naphtalen-2-yl]-piperidin-1-yl]-butylamine
[0249] The same method was employed as in the preparation of intermediate 8 but starting from intermediate 42 gave the title compound as yellow oil (2.1 g, 7.9 mmol) in a 79% yield.
[0250]
1
H NMR (CDCl3, 300 MHz) δ 8.1 (d, 1H), 7.8 (d, 1H), 7.6 (d, 1H), 7.3 (m, 3H), 6.2 (m, 1H), 5.5 (d, 1H), 5.3 (d, 1H), 4.4 (d, 2H), 3.8 (t, 2H), 3.3 (m, 1H), 3.0 (d, 2H), 2.4 (t, 2H), 2.1 (t, 2H), 2.0 (m, 2H), 1.7 (m, 4H), 1.6 (m, 2H).
1-[4-(1-Propoxy-naphtalen-2-yl)-piperidin-1-yl]-ethanone
[0251] The same method was employed as in the preparation of intermediate 40 in using the 1-Bromo-propane to give the title compound as a colorless powder (5.8 g, 19 mmol) in a 84% yield.
[0252]
1
H NMR (CDCl3, 300 MHz) δ 8.1 (d, 1H), 7.8 (d, 1H), 7.5 (d, 1H), 7.3 (m, 2H), 7.1 (d, 1H), 4.8 (d, 1H), 3.9 (m, 3H), 3.3 (m, 1H), 3.2 (m, 1H), 2.5 (m, 1H), 2.1 (s, 3H), 1.8 (m, 2H), 1.8 (m, 4H), 1.1 (t, 3H).
4-(1-Propoxy-naphtalen-2-yl)-piperidine
[0253] The same method was employed as in the preparation of intermediate 12 but starting from intermediate 44 gave the title compound as yellow oil (4.3 g, 16 mmol) in a 84% yield.
[0254]
1
H NMR (CDCl3, 300 MHz) δ 8.1 (d, 1H), 7.8 (d, 1H), 7.5 (d, 1H), 7.3 (m, 2H), 7.1 (d, 1H), 4.8 (d, 1H), 3.9 (m, 3H), 3.3 (m, 1H), 3.2 (m, 1H), 2.5 (m, 1H), 1.8 (m, 2H), 1.8 (m, 4H), 1.1 (t, 3H).
2-{4-[4-(1-Propoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0255] The same method was employed as in the preparation of intermediate 7 but starting from intermediate 45 gave the title compound as yellow crystals (5.3 g, 11 mmol) in a 75% yield.
[0256]
1
H NMR (CDCl3, 300 MHz) δ 8.1 (d, 1H), 7.9 (m, 3H), 7.8 (m, 2H), 7.6 (d, 1H), 7.3 (m, 3H), 3.8 (t, 2H), 3.3 (m, 1H), 3.0 (d, 2H), 2.4 (t, 2H), 2.1 (t, 2H), 2.0 (m, 2H), 1.7 (m, 8H), 1.6 (m, 2H), 1.1 (t, 3H).
4-[4-(1-Propoxy-naphtalen-2-yl)-piperidin-1-yl]-butylamine
[0257] The same method was employed as in the preparation of intermediate 8 but starting from intermediate 46 gave the title compound as a yellow oil (3.5 g, 10 mmol).
[0258]
1
H NMR (CDCl3, 300 MHz) δ 8.05 (d, 1H), 7.8 (d, 2H), 7.6 (d, 1H), 7.3 (m, 3H), 3.8 (t, 2H), 3.3 (m, 1H), 3.0 (d, 2H), 2.4 (t, 2H), 2.1 (t, 2H), 2.0 (m, 2H), 1.7 (m, 8H), 1.6 (m, 2H), 1.1 (t, 3H).
1-[4-(1-Cyclopropylmethoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-ethanone
[0259] To a solution of intermediate 35 (11.2 g, 0.041 mol) in dry acetone and DMF (200 mL, 1/1) was added Cs2CO3 (20.05 g, 1.5 eq.) and Bromomethylcyclopropane (6.09 g, 1.1 eq.). The reaction was stirred at 55° C. for 13 hours. After cooling, the reaction was filtered off and washed with acetone. The filtrate was evaporated under reduced pressure to give the title compound as an yellow oil in a quantitative yield. The crude product was used in the next step without purification.
4-(1-Cyclopropylmethoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidine
[0260] The same method was employed as in the preparation of intermediate 12 but starting from the intermediate 48 to give the title compound as an oil in a 90% yield.
[0261]
1
H NMR (CDCl3, 300 MHz) δ 6.95 (d, 1H), 6.8 (d, 1H), 3.5 (m, 2H), 2.9 (m, 2H), 2.8 (m, 4H), 2.3 (m, 2H), 1.9 (m, 2H), 1.8 (m, 4H), 1.4 (m, 4H), 1.1 (m, 1H), 0.45 (m, 2H), 0.25 (m, 2H).
2-{4-[4-(1-Cyclopropylmethoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0262] The same method was employed as in the preparation of intermediate 7 but starting from the intermediate 49 to give after flash chromatography using (DCM/MeOH, 95/5 and 90/10) as eluent, the title compound as an orange oil in a 80% yield.
[0263]
1
H NMR (CDCl3, 300 MHz) δ 7.8 (m, 2H), 7.6 (m, 2H), 6.9 (d, 1H), 6.7 (d, 1H), 3.7 (m, 2H), 3.4 (m, 2H), 3.0 (m, 2H), 2.6 (m, 4H), 2.4 (m, 2H), 1.9 (m, 2H), 1.7 (m, 13H), 1.1 (m, 1H), 0.45 (m, 2H), 0.25 (m, 2H).
4-[4-(1-Cyclopropylmethoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butylamine
[0264] The same method was employed as in the preparation of intermediate 8 but starting from intermediate 50 gave the title compound as an orange oil in a 90% yield.
[0265] LC/MS(APCI): [M+H+] 357 C23H36N2O
1-[4-(1-methoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-ethanone
[0266] The same method was employed as in the preparation of intermediate 17 but starting from intermediate 35 gave the title compound as white solid in a 57% yield.
[0267] LC/MS(APCI): [M+H+] 287 C18H25NO2
4-(1-methoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidine
[0268] The same method was employed as in the preparation of intermediate 12 but starting from intermediate 52 gave the title compound as a yellow oil in a 90% yield.
[0269] LC/MS(APCI): [M+H+] 246 C16H23NO
2-{4-[4-(1-methoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0270] The same method was employed as in the preparation of intermediate 7 but starting from intermediate 53 gave the title compound as a oil in a quantitative yield.
[0271] LC/MS(APCI): [M+H+] 447 C28H34N2O3
4-[4-(1-methoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butylamine
[0272] The same method was employed as in the preparation of intermediate 8 but starting from intermediate 54 gave the title compound as a yellow oil in a 83% yield.
[0273] LC/MS(APCI): [M+H+] 317 C20H32N2O
4′-Methanesulfonyl-biphenyl-4-carboxylic Acid
[0274] The same method was employed as in the preparation of intermediate 1 but starting from the 4-Bromophenylmethanesulfone gave the title compound as white powder in a 56% yield.
[0275] LC/MS(ES): M+276 C14H12SO4
5-Isopropyl-2-(1,2,3,6-tetrahydro-pyridin-4-yl)-phenol
[0276] A solution of 3-Isopropyl-phenol (68.1 g 0.5 mol) and 4-Piperidone hydrate hydrochloride (92.1 g, 1.2 eq.) in acetic acid (300 mL) was treated with HCl gaz for 10 min. The mixture was stirred at 95° C. for 30 min. After cooling to rt, the mixture was treated again with HCl gaz for 10 min. The resulting solution was allowed to stir at rt for 4 days. The solvent was evaporated under reduced pressure to give a colorless oil (110.0 g 0.5 mol). The product was used without further purification.
Acetic Acid 2-(1-acetyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-isopropyl-phenyl Ester
[0277] To a solution of intermediate 57 (110.0 g, 0.5 mol) in pyridine (1000 mL) was added acetic anhydride (300 mL). The mixture was stirred at rt for 12 hours. The solvents were evaporated under reduce pressure. The oil was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give the title compound (150.0 g, 0.5 mol) as a yellow oil in a quantitative yield.
[0278] GC/MS: M+C18H23NO3 301
1-[4-(2-Hydroxy-4-isopropyl-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-ethanone
[0279] To a solution of intermediate 58 (150.0 g, 0.5 mol) in MeOH (1500 mL) was added K2CO3 (207.0 g, 3 eq.) and the mixture was stirred under reflux for 12 hours. The solution was filtered and the methanol was evaporated. The oil was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give the title compound (76.0 g, 0.29 mol) as an orange oil.
[0280] GC/MS: M+C16H21NO2 259
1-[4-(2-Hydroxy-4-isopropyl-phenyl)-piperidin-1-yl]-ethanone
[0281] To a solution of intermediate 59 (56.0 g, 0.22 mol) in EtOH (1400 mL) was added Pd/C, 10% (5.6 g) and the reaction was stirred under under an atmospheric pressure of hydrogen for 48 hours. The reaction mixture was filtered through a bed of celite. The filtrate was evaporated under reduced pressure to give the title compound (54.5 g, 0.21 mol).
[0282] GC/MS: M+C16H23NO2 261
1-[4-(4-Isopropyl-2-methoxy-phenyl)-piperidin-1-yl]-ethanone
[0283] To a solution of intermediate 60 (54.5 g, 0.21 mol) in dry acetone (1000 mL) was added K2CO3 (43.0 g, 1.5 eq.) and methyl iodide (130 mL, 10 eq.). The reaction was stirred at 60° C. for 12 hours. After cooling, the reaction was filtered off and evaporated under reduced pressure. The oil was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give the title compound (55.7 g, 0.203 mol) as a yellow oil.
[0284] GC/MS: M+C17H25NO2 275
4-(4-Isopropyl-2-methoxy-phenyl)-piperidine
[0285] To a solution of intermediate 61 (55.7 g, 0.200 mol) in EtOH (500 mL) was added a solution of NaOH (270 mL) in H2O (270 mL). The reaction was stirred under reflux for 12 hours. After cooling, the reaction was concentrated under reduced pressure, was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give the title compound (48.8 g, 0.20 mol) as a yellow oil.
[0286] GC/MS: M+C15H23NO 233
2-{4-[4-(4-Isopropyl-2-methoxy-phenyl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0287] The same method was employed as in the preparation of intermediate 7 but starting from intermediate 62 gave the title compound as a yellow oil in a quantitative yield.
[0288]
1
H NMR (CDCl3, 250 MHz) δ 7.8 (m, 2H), 7.65 (m, 2H), 7.05 (d, 1H), 6.7 (dd, 1H), 6.6 (s, 1H), 3.7 (s, 3H), 3.65 (m, 3H), 2.9 (m, 1H), 3.0 (bd, 2H), 2.8 (m, 2H), 2.3 (m, 2H), 2.0 (m, 2H), 1.70-1.5 (m, 6H), 1.2 (d, 6H).
4-[4-(4-Isopropyl-2-methoxy-phenyl)-piperidin-1-yl]-butylamine
[0289] The same method was employed as in the preparation of intermediate 8 but starting from intermediate 28 gave the title compound as an oil in a 93% yield.
[0290]
1
H NMR (CDCl3, 250 MHz) δ 7.05 (m, 1H), 6.7 (dd, 1H), 6.6 (d, 1H), 3.8 (s, 3H), 3.1 (bd, 2H), 2.8 (m, 2H), 2.7 (t, 2H), 2.3 (m, 2H), 2.0-1.3 (m, 12H), 1.15 (d, 6H).
2-(1-Benzyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-methyl-phenol
[0291] To a solution of m-Cresol (20.0 g, 0.185 mol) and 1-Benzyl-4-piperidone (35.0 g, 1.0 eq.) was added dropwise BF3-Et2O (71 mL, 3.0 eq). The mixture was stirred at 100° C. for 24 hours. After cooling to rt, the mixture was treated with a 1N HCl solution (400 mL). The resulting solution was extracted with DCM. The organic layer was dried over Na2SO4 and evaporated to dryness to give an oil which was crytallized in cyclohexane to give the title compound (40.0 g, 0.14 mol) as a yellow powder.
[0292] GC/MS: M+C19H21NO 279
2-(1-Benzyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-ethyl-phenol
[0293] A solution of 3-Ethyl-phenol (6.1 g, 0.05 mol) and 1-Benzyl-4-piperidone (10.0 g 1.05 eq.) in acetic acid (100 mL) was treated with HCl gaz for 10 min. The mixture was stirred at 95° C. for 30 min. After cooling to rt, the mixture was treated again with HCl gaz for 5 min. The resulting solution was allowed to stir at rt for 4 days. The solvent was evaporated under reduced pressure and the residue was diluted with H2O and extracted with DCM. The organic layer was washed with a 2N NaOH solution, H2O and brine, dried over Na2SO4 and evaporated to dryness. The residue was flash chromatographed using MeOH/DCM (5/95) to give the title compound (8.0 g, 0.027 mol) as a yellow oil in 54% yield.
[0294] GC/MS: M+C20H23NO 293
1-Benzyl-4-[2-(tert-butyl-dimethyl-silanyloxy)-4-ethyl-phenyl]-1,2,3,6-tetrahydro-pyridine
[0295] To a solution of intermediate 66 (3.0 g, 0.01 mol) in DMF (20 mL) was added at 50° C. NaH (1.1 eq.) (60% in oil dispersion). The reaction was stirred for 15 min and the terbutyl dimethyl silyl chloride (1.65 g, 0.011 mol) was added and the reaction was stirred for 18 hours at rt.
[0296] The reaction was concentrated in vacuo and the residue was diluted with DCM, washed with water, dried over Na2SO4 and evaporated off. The title compound was obtained (3.1 g, 7.6 mmol) as a yellow oil in a 77% yield.
[0297] GC/MS: M+C26H37NOSi 407
4-[2-(tert-Butyl-dimethyl-silanyloxy)-4-ethyl-phenyl]-piperidine
[0298] To a solution of intermediate 67 (3.1 g, 7.6 mmol) in EtOH (100 mL) was added Pd/C, 10% (0.3 g) and the reaction was stirred under an atmospheric pressure of hydrogen for 24 hours. The reaction mixture was filtered through a bed of celite. The filtrate was evaporated under reduced pressure to give the title compound (2.0 g, 6.2 mmol) as an oil in a 83% yield.
[0299] GC/MS: M+C19H33NOSi 319
2-(4-{4-[2-(tert-Butyl-dimethyl-silanyloxy)-4-ethyl-phenyl]-piperidin-1-yl}-butyl)-isoindole-1,3-dione
[0300] A solution of intermediate 68 (2.0 g, 6.2 mmol) in acetone (800 mL) was treated with K2CO3 (1.7 g, 2.0 eq.) and N-(4-Bromobutyl)-phtalimide (2.1 g, 1.2 eq.). The resulting mixture was stirred under reflux for 6 hours. After cooling to rt the reaction mixture was filtered off. The cake was washed with acetone. The filtrate was evaporated off to give after flash chromatography using (DCM/MeOH, 95/5) as eluent the title compound (2.1 g, 4 mmol) as yellow crystals in a 66% yield.
[0301] GC/MS: M+C31H44N2O3Si 520
4-{4-[2-(tert-Butyl-dimethyl-silanyloxy)-4-ethyl-phenyl]-piperidin-1-yl}-butylamine
[0302] A solution of intermediate 69 (2.1 g, 4 mmol) in MeOH (50 mL) was treated with hydrazine hydrate (0.23 mL, 1.2 eq.). The resulting mixture was stirred at 60° C. for 5 hours. After evaporation under reduced pressure the residue was taken up in water and treated with a concentrated HCl solution until PH=4. The white precipitate was filtered off, washed with water and the filtrate was treated with a concentrated NaOH solution until PH=13. Extraction with DCM, drying over Na2SO4 and filtration gave the title compound (0.7 g, 1.8 mmol) as a yellow oil in a 45% yield.
[0303] GC/MS: M+C23H42N2OSi 390
4′-Cyano-biphenyl-4-carboxylic Acid (4-{4-[2-(tert-butyl-dimethyl-silanyloxy)-4-ethyl-phenyl-piperidin-1-yl}-butyl)-amide
[0304] To a solution of intermediate 70 (0.7 g, 1.8 mmol) in dry DCM (25 mL) was added the available 4′-Cyano-biphenyl-4-carboxylic acid (0.36 g, 0.9 eq.), EDCl (0.68 g, 2.0 eq.), HOBt (0.48 g, 2.0 eq.) and TEA (0.5 mL, 2.0 eq.). The resulting mixture was stirred for 5 hours at rt. The residue was washed with water and brine. The organic layer was dried over Na2SO4 and evaporated off. Purification by flash chromatography using DCM/MeOH, 90/10 as eluent gave the title compound (0.7 g, 1.17 mmol) as white crystals in a 73% yield.
[0305] MP: 140° C.
[0306] LC/MS: [M+H+] 596 C37H49N3O2Si
1-[4-(1-Hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-3,6-dihydro-2H-pyridin-1-yl]-ethanone
[0307] The same method was employed as in the preparation of intermediate 65 but starting from the 5,6,7,8-tetrahydro-1-naphtol and N-Acetyl-piperidone to give the title compound as a powder after crystallization in CH3CN in a 100% yield.
[0308] GC/MS: M+C17H21NO2 271
1-[4-(1-Hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-ethanone
[0309] To a solution of intermediate 72 (55.0 g, 0.203 mol) in AcOH (500 mL) was added Pd/C, 10% (2 g) and the reaction was stirred under an atmospheric pressure of hydrogen at 50° C. for 24 hours. The mixture was filtered through a bed of celite. The filtrate was evaporated under reduced pressure to give the title compound (55.0 g, 0.201 mol) as a yellow powder.
[0310] GC/MS: M+C17H22NO2 273
2-Piperidin-4-yl-5,6,7,8-tetrahydro-naphtalen-1-ol
[0311] To a solution of intermediate 73 (27.0 g, 0.099 mol) in EtOH (750 mL) was added a solution of NaOH (250 mL) in H2O (250 mL). The reaction was stirred under reflux for 16 hours. After cooling, the reaction was concentrated under reduced pressure, was diluted with DCM and washed with water. The organic layer was dried over Na2SO4 and evaporated to dryness to give after flash chromatography using DCM/MeOH/NH4OH 30,30,30 as eluent, the title compound (9.7 g, 0.042 mol) as a pink gummy oil in a 42.5% yield.
[0312]
1
H NMR (CDCl3, 300 MHz) δ 7.9 (bs, 1H), 6.8 (d, 1H), 6.6 (d, 1H), 3.4 (m, 2H), 3.1 (m, 2H), 2.8 (m, 4H), 1.8-1.4 (m, 10H).
2-(4,4-Diethoxy-butyl)-isoindole-1,3-dione
[0313] To a solution of Isobenzofuran-1,3-dione (10.0 g, 0.068 mol) in toluene (200 mL) were added 4-Aminobutyraldehyde diethyl acetal (14.5 g, 1.2 eq.) and TEA (14.0 mL, 1.5 eq.). The reaction was stirred to reflux for 16 hours. The toluene was removed under vacuo and the residue was dissolved in Et2O and washed with water. The organic phase was dried over Na2SO4 and concentrated under vacuo to give the title compound (21.0 g, 1.0 eq.) as an oil in a quantitative yield.
[0314] GC/MS: M+C16H21NO4 291
4-(1,3-Dioxo-1,3-dihydro-isoindole-2-yl)-butyraldehyde
[0315] To a solution of intermediate 17 (21.0 g, 0.068 mol) in acetone (200 mL) was added a 1N HCl solution (100 mL) and the reaction was stirred to reflux for 2 hours. The solvent Was then evaporated and a 1N NaOH solution (200 mL) was added. The product was extracted with DCM and the organic phase was dried over Na2SO4 and concentrated under vacuo. The title compound was obtained as a yellow oil (8.4 g, 0.039 mol) in a 59% yield.
[0316]
1
H NMR (CDCl3, 300 MHz) δ 9.6 (s, 1H), 7.8 (m, 2H), 7.4 (m, 2H), 3.6 (t, 2H), 2.4 (t, 2H), 1.8 (m, 2H).
[0317] Ref: J. Med. Chem. (1992), 35, 3239-46.
2-{4-[4-(1-Hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0318] To a solution of intermediate 74 in dry THF and MeOH was added the intermediate 76. The reaction was stirred at rt for 30 min and AcOH (1.5 eq) was added. Then sodium triacetoxyborohydride (1.2 eq.) was added and the reaction was stirred for 24 hours at 80° C. After cooling, the solvent was evaporated and subjected to flash chromatography using (DCM/MeOH, 90/10 and 1% ammoniac solution) as eluent to give the title compound as a gummy oil in a 46% yield.
[0319]
1
H NMR (CDCl3, 300 MHz) δ 7.9 (m, 2H), 7.75 (m, 2H), 6.9 (d, 1H), 6.8 (d, 1H), 6.4 (bs, 1H), 3.85 (m, 2H), 3.5 (m, 2H), 3.0 (m, 1H), 2.9 (m, 2H), 2.8 (m, 2H), 2.5 (m, 4H), 2.1 (m, 2H), 1.87 (m, 10H).
2-[1-(4-Amino-butyl)-piperidin-4-yl]-5,6,7,8-tetrahydro-naphtalen-1-ol
[0320] The same method was employed as in the preparation of intermediate 70 but starting from intermediate 77 to give the title compound as a red oil in a 90% yield.
[0321]
1
H NMR (CDCl3, 300 MHz) δ 7.0 (d, 1H), 6.6 (d, 1H), 3.1 (m, 2H), 2.9 (m, 1H), 2.65 (m, 4H), 2.6 (m, 2H), 2.45 (m, 2H), 2.1 (m, 2H), 1.85 (m, 8H), 1.5 (m, 6H).
1-[4-(1-Hydroxy-naphtalen-2-yl)-3,6-dihydro-2H-pyridin-1-yl]-ethanone
[0322] The same method was employed as in the preparation of intermediate 65 but starting from the 1-Naphtol gave the title compound as a white solid in a 54% yield.
[0323] GC/MS: M+C17H17NO2 267
1-[4-(1-Hydroxy-naphtalen-2-yl)-piperidin-1-yl]-ethanone
[0324] A solution of intermediate 73 (29.0 g, 0.112 mol) in a mixture of cyclohexene (450 mL), MeOH (100 mL), THF (350 mL) was treated with Pd(OH)2, 50% (14 g). The resulting solution was allowed to stir at reflux for 4 days. After cooling, the reaction mixture was filtered through a bed of celite. The filtrate was evaporated to dryness to give the title compound as a white solid (22.0 g, 0.082 mol) in a 73% yield after recrystallization from CH3CN.
[0325] LC/MS: [M+H+] C17H19NO2 270
2-Piperidin-4-yl-naphtalen-1-ol
[0326] The same method was employed as in the preparation of intermediate 74 but starting from the intermediate 80 gave the title compound as a brown solid in a quantitative yield.
[0327]
1
H NMR (DMSO, d6, 300 MHz) δ 9.3 (s, 1H), 8.25 (dd, 1H), 7.8 (dd, 1H), 7.5 (m, 3H), 7.25 (m, 1H), 3.45 (m, 3H), 3.1 (m, 2H), 2.9 (m, 4H).
2-{4-[4-(1-Hydroxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-isoindole-1,3-dione
[0328] The same method was employed as in the preparation of intermediate 77 but starting from the intermediate 81 gave the title compound as a pink solid in a 61% yield.
[0329]
1
H NMR (CDCl3, 300 MHz) δ 8.3 (dd, 2H), 7.95 (m, 2H), 7.8 (m, 3H), 7.6-7.2 (m, 4H), 3.85 (m, 2H), 3.25 (m, 2H), 2.85 (m, 2H), 2.55 (m, 2H), 2.35 (m, 2H), 1.95 (m, 2H), 1.8 (m, 4H).
2-[1-(4-Amino-butyl)-piperidin-4-yl]-naphtalen-1-ol
[0330] The same method was employed as in the preparation of intermediate 70 but starting from intermediate 82 to give the title compound as a yellow solid in a 79% yield.
[0331] LC/MS(ES): M+C19H26N2O 298
4′-Acetyl-biphenyl-4-carboxylic Acid Ethyl Ester
[0332] To a solution of 16 g (0.058 mol.) of 4-iodo-benzoic acid ethyl ester in toluene (200 mL) was added successively 3.35 g (0.05 eq.) of tetrakis (triphenylphosphine) palladium (0), 69 ml of a 2M solution of Na2CO3 and 7.5 g (3 eq.) of lithium chloride. After 15 minutes of stirring was added a solution of 10 g (1.05 eq.) of 4-acetylphenyl boronic acid in EtOH (50 mL). Then, the mixture was refluxed for 24 hours. After cooling, the solvents were evaporated to dryness. The residue was poured in water (300 mL) and the organic phase was separated, dried over Na2SO4 and evaporated off. After purification by flash chromatography (using DCM as eluent), the tilte compound (12.0 g, 0.045 mol) was obtained as a powder in a 73% yield.
[0333] GC/MS: M+C17H16O3 268
4′-Acetyl-biphenyl-4-carboxylic Acid
[0334] To a solution of intermediate 84 (12.0 g, 0.045 mol) in EtOH (200 mL) was added a 1N NaOH solution (85 mL, 2 eq.) and the reaction was reflux for 16 hours. After cooling, the reaction was concentrated in vacuo and a 1N HCl solution (100 mL) was added. The precipitate obtained was filtered off, washed with water and dried to give the title compound as a colorless powder (10 g, 0.042 mol) in a 93% yield
[0335] GC/MS: M+C15H12O3 240
1-Benzyl-4-[2-(tert-butyl-dimethyl-silanyloxy)-4-methyl-phenyl]-1,2,3,6-tetrahydro-pyridine
[0336] The same method was employed as in the preparation of intermediate 9 but starting from the intermediate 65 gave the title compound as a yellow oil in a 30% yield.
[0337] GC/MS: M+393 C25H35NOSi
4-[2-(tert-Butyl-dimethyl-silanyloxy)-4-methyl-phenyl]-pyridine
[0338] The same method was employed as in the preparation of intermediate 68 but starting from intermediate 86 to give the title compound as a white powder in a quantitative yield.
[0339] GC/MS: M+C18H31NOSi 305
2-(4-{4-[2-(tert-Butyl-dimethyl-silanyloxy)-4methyl-phenyl]-pyridin-1-yl}-butyl)-isoindole-1,3-dione
[0340] The same method was employed as in the preparation of intermediate 69 but starting from intermediate 87 gave the title compound as a yellow oil in a 40% yield which crystallise in MeOH.
[0341] GC/MS: M+C30H42N2O3Si 506
4-{4-[2-(tert-Butyl-dimethyl-silanyloxy)-4-methyl-phenyl]-pyridin-1-yl}-butylamine
[0342] The same method was employed as in the preparation of intermediate 70 but starting from intermediate 88 gave the title compound as a yellow oil in a 96% yield.
[0343] LC/MS(APCI): [M+H+] C22H40N2OSi 377
4′-Cyano-biphenyl-4-carboxylic Acid (4-{4-[2-(tert-butyl-dimethyl-silanyloxy)4-methyl-phenyl-piperidin-1-yl}-butyl)-amide
[0344] The same method was employed as in the preparation of intermediate 71 but starting from intermediate 89 gave the title compound as a white oil in a 36% yield.
[0345] LC/MS(APCI): [M+H+] C36H47N3O2Si 582
4′-Trifluoromethyl-biphenyl-4-carboxylic Acid {4-[4-(2-ethoxy-4-methyl-phenyl)-piperidin-1-yl]-butyl-}-amide
[0346] To a solution of intermediate 8 (0.58 g, 2 mmol) in dry DCM (20 mL) was added the intermediate 1 (0.48 g, 0.9 eq.), EDCl (0.46 g, 1.2 eq.), HOBt (0.32 g, 1.2 eq.) and TEA (0.34 mL, 1.2 eq.). The resulting mixture was stirred for 16 hours at rt. The residue was washed with a 1N NaOH solution and brine. The organic layer was dried over Na2SO4 and evaporated off. Recrystallization from CH3CN gave the title compound as white crystals in a 65% yield.
[0347] MP: 191° C.
[0348] LC/MS: [M+H+] 539 C32H37F3N2O2
4′-Trifluoromethyl-biphenyl-4-carboxylic Acid [4-[4-(2-cyclopropylmethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl]-amide
[0349] A solution of intermediate 14 (1.65 g, 5 mmol) in DMF was treated with intermediate 1 (1.27 g, 0.95 eq.), HATU (1.83 g, 0.95 eq.) and TEA (2.1 mL, 3 eq.). The resulting mixture was stirred for 18 hours at rt. The solvent was evaporated off. The residue was taken up in water, and a 1N NaOH (5 mL) solution was added and the mixture was sonicated during 5 minutes. The resulting precipitate was filtrated off and washed 3 times with water (15 mL). The white powder was dried under vacuo. Recrystallization from EtOH gave the title compound as a white powder in a 29% yield.
[0350] MP: 247-249° C.
[0351] LC/MS: [M+H+] 579 C35H41F3N2O2
4′-Chloro-biphenyl-4-carboxylic Acid {4-[4-(1-methoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0352] The same method was employed as in the preparation of example 1 but starting from intermediate 20 and intermediate 2 gave the title compound as white crystals after recrystallization from CH3CN in a 72% yield.
[0353] MP: 197° C.
[0354] LC/MS: [M+H+] 527 C33H35ClN2O2
4′-Chloro-biphenyl-4-carboxylic Acid {4-[4-(2-methoxy-naphtalen-1-yl)-piperidin-1-yl]-butyl}amide
[0355] The same method was employed as in the preparation of example 1 but starting from intermediate 25 and intermediate 2 gave the title compound as a yellow powder after recrystallization in CH3CN in a 50% yield.
[0356] MP: 149° C.
[0357] LC/MS: [M+H+] 527 C33H35ClN2O2
4′-Cyano-biphenyl-4-carboxylic Acid {4-[4-(2-ethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-amide
[0358] The same method was employed as in the preparation of example 1 but starting from intermediate 33 and the available 4′-Cyano-biphenyl-4-carboxylic acid to give the title compound as white needles after recrystallization from CH3CN in a 30% yield.
[0359] MP: 165° C.
[0360] LC/MS: [M+H+] 510 C33H39N3O2
4′-Cyano-biphenyl-4-carboxylic Acid {4-[4-(1-methoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0361] The same method was employed as in the preparation of example 1 but starting from intermediate 20 and the available 4′-Cyano-biphenyl-4-carboxylic acid gave the title compound as white solid after recrystallization from CH3CN in a 45% yield.
[0362] MP: 180° C.
[0363] LC/MS: [M+H+] 518 C34H35N3O2
4′Trifluoromethyl-biphenyl-4-carboxylic Acid {4-[4-(1-isobutoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0364] The same method was employed as in the preparation of example 1 but starting from intermediate 39 gave the title compound as white crystals after recrystallization from CH3CN in a 54% yield.
[0365] MP: 165° C.
[0366] LC/MS (APCI): [M+H+] C37H45F3N2O2 607
4′-Trifluoromethyl-biphenyl-4-carboxylic Acid {4-[4-(1-allyloxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0367] The same method was employed as in the preparation of example 1 but starting from intermediate 43 to give the title compound as colorless crystals in a 45% yield after recrystallisation from CH3CN
[0368] MP: 180-181° C.
[0369] LC/MS (APCI): [M+H+] C36H37F3N2O2 587
4′-Trifluoromethyl-biphenyl-4-carboxylic Acid {4-[4-(1-propoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0370] The same method was employed as in the preparation of example 1 but starting from intermediate 47 to give the title compound as white crystals in a 12% yield after recrystallisation from CH3CN
[0371] MP: 191-192° C.
[0372] LC/MS (APCI): [M+H+] C36H39F3N2O2 589
4′-Trifluoromethyl-biphenyl-4-carboxylic Acid {4-[4-(1-Cyclopropylmethoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0373] The same method was employed as in the preparation of example 1 but starting from intermediate 51 gave the title compound as white needles after recrystallization from CH3CN/MeOH in a 48% yield.
[0374] MP: 181° C.
[0375] LC/MS (APCI): [M+H+] 605 C37H43F3N2O2
4′-Cyano-biphenyl-4-carboxylic Acid {4-[4-(1-methoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0376] The same method was employed as in the preparation of example 5 but starting from intermediate 55 gave the title compound as white solid after recrystallization from MeCN in a 39% yield.
[0377] MP: 154° C.
[0378] LC/MS (APCI): [M+H+] 522 C34H39N3O2
4′-Methanesulfonyl-biphenyl-4-carboxylic Acid {4-[4-(2-ethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-amide
[0379] The same method was employed as in the preparation of example 1 but starting from intermediate 33 and intermediate 60 to give the title compound as white crystals after flash chromatography using DCM/MeOH 90/10 as eluent in a 2% yield.
[0380] MP: 179-180° C.
[0381] LC/MS: [M+H+] 563 C33H42N2O4S
4-Methyl-2-(4-trifluromethyl-phenyl)-thiazole-5-carboxylic acid {4-[4-(4isopropyl-2-methoxy-phenyl)-piperidin-1-yl]-butyl}-amide
[0382] The same method was employed as in the preparation of example 1 but starting from intermediate 64 and 4-Methyl-2-(4-trifluromethyl-phenyl)-thiazole-5-carboxylic acid gave the title compound as white crystals after recrystallization from MeCN in a 54% yield.
[0383] MP: 170° C.
[0384] Analysis for C31H38F3N3O2S, (0.4H2O): Calculated: C, 64.09; H, 6.73; N, 7.23. Found: C, 64.28; H, 7.07; N, 7.28
4′-Cyano-biphenyl-4-carboxylic Acid {4-[4-(2-hydroxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-amide
[0385] To a solution of intermediate 71 (0.1 g, 0.17 mmol) in THF (10 mL) was added the tetrabutylammonium fluoride (1.2 eq.). The reaction was stirred to rt during 15 min. Then H2O (10 mL) was added and the organic phase was decanted, dried over Na2SO4 and evaporated off. The title compound was obtained as white crystals (0.055 g, 0.1 mmol) after recrystallization from MeOH in a 68% yield.
[0386] MP: 252° C.
[0387] LC/MS(APCI): [M+H+] 482 C31H35N3O2
4′-Cyano-biphenyl-4-carboxylic Acid {4-[4-(1-hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0388] The same method was employed as in the preparation of intermediate 71 but starting from intermediate 78 to give the title compound as a white powder after formation of chlorhydrate from a hot HCl 1N/EtOH solution in a 49% yield.
[0389] MP: 252° C.
[0390] LC/MS(ES): M+507 C33H37N3O2
4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(1-hydroxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0391] The same method was employed as in the preparation of intermediate 71 but starting from intermediate 83 to give the title compound as a colorless solid in a 55% yield.
[0392] MP: 135-140° C.
[0393] LC/MS(APCI): [M+H+] 504 C33H33N3O2
4′-Acetyl-biphenyl-4-carboxylic Acid {4-[4-(1-hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide
[0394] The same method was employed as in the preparation of intermediate 71 but starting from intermediate 78 and 85 to give the title compound as a colorless powder after purification by flash chromatography (using DCM/MeOH 80/20 as eluent) and crystallisation in iPr2O in a 49% yield.
[0395] MP: 180-185° C.
[0396] LC/MS (APCI): [M+H+] 525 C34H40N2O3
4′-Cyano-biphenyl-4-carboxylic Acid {4-[4-(2-hydroxy-4-methyl-phenyl)-piperidin-1-yl]-butyl}-amide
[0397] The same method was employed as in the preparation of example 14 but starting from intermediate 90 to give the title compound as a white crystals in a 34% yield.
[0398] MP: 184° C.
[0399] LC/MS(APCI): [M+H+] 468 C30H33N3O2
[0400] Biological Assays
[0401] In Vitro Assay:
[0402] HepG2 cells, stably transfected with a construct comprising the the LDL-r promoter and the luciferase reporter gene, were seeded at 50.000 cells/well in 96 well plates. After 1 day, cells were incubated with compounds for 24 hours in RPMI medium containing 2% of lipoprotein-deficient serum. Compounds were tested from 10−6M to 10−9M. Cell lysates were prepared and the luciferase activity was measured by the luciferase assay system (Promega). Induction of luciferase activity was calculated taking untreated cells as control and ED50 of each compounds was determinated compared to the ED50 of an internal standart.
[0403] In Vivo Assay:
[0404] Compounds were prepared for oral administration by milling with 0.5% hydroxypropylmethylcellulose and 5% Tween 80. Hamsters were fed for 2 weeks with a diet containing 0.2% of cholesterol and 10% of coconut oil. Then compounds were administrated once a day for 3 days, from 20 to 0.2 mg/kg. Plasma lipid levels including total cholesterol, VLD/LDL cholesterol, VLD/LDL triglycerides and HDL-cholesterol were determinated after ultracentrifugation (density 1.063 g/ml to separate VLD/LDL fraction and HDL fraction) using the Biomerieux enzymatic kit. Reductions in VLD/LDL cholesterol and TG plasmatic levels were calculated taking solvant treated animals as control and ED50 of each compound was determined.
[0405] Biological Results
2|
|
ExampleIn vitro (IC50) (nm)In vivo (ED50) (mg/kg)
|
|
3102
5102
11101
|
[0406] Tablet Compositions
[0407] The following compositions A and B can be prepared by wet granulation of ingredients (a) to (c) and (a) to (d) with a solution of povidone, followed by addition of the magnesium stearate and compression.
3|
|
Composition A
mg/tabletmg/tablet
|
(a) Active ingredient250250
(b) Lactose B.P.21026
(c) Sodium Starch Glycollate2012
(d) Povidone B.P.159
(e) Magnesium Stearate53
500300
|
[0408]
4
|
|
Composition B
|
mg/tablet
mg/tablet
|
|
(a) Active ingredient
250
250
|
(b) Lactose 150
150
—
|
(c) Avicel PH 101
60
26
|
(d) Sodium Starch Glycollate
20
12
|
(e) Povidone B.P.
15
9
|
(f) Magnesium Stearate
5
3
|
500
300
|
|
[0409]
5
|
|
Composition C
|
mg/tablet
|
|
Active ingredient
100
|
Lactose
200
|
Starch
50
|
Povidone
5
|
Magnesium Stearate
4
|
359
|
|
[0410] The following compositions D and E can be prepared by direct compression of the admixed ingredients. The lactose used in composition E is of the direct compression type.
6|
|
Composition D
mg/tablet
|
Active ingredient250
Magnesium Stearate4
Pregelatinised Starch NF15146
400
|
[0411]
7
|
|
Composition E
|
mg/tablet
|
|
Active ingredient
250
|
Magnesium Stearate
5
|
Lactose
145
|
Avicel
100
|
500
|
|
[0412]
8
|
|
Composition F (Controlled release composition)
|
mg/tablet
|
|
(a)
Active ingredient
500
|
(b)
Hydroxypropylmethylcellulose
112
|
(Methocel K4M Premium)
|
(c)
Lactose B.P.
53
|
(d)
Povidone B.P.C.
28
|
(e)
Magnesium Stearate
7
|
700
|
|
[0413] The composition can be prepared by wet granulation of ingredients (a) to (c) with a solution of povidone, followed by addition of the magnesium stearate and compression.
[0414] Composition G (Enteric-Coated Tablet)
[0415] Enteric-coated tablets of Composition C can be prepared by coating the tablets with 25 mg/tablet of an enteric polymer such as cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethyl-cellulose phthalate, or anionic polymers of methacrylic acid and methacrylic acid methyl ester (Eudragit L). Except for Eudragit L, these polymers should also include 10% (by weight of the quantity of polymer used) of a plasticizer to prevent membrane cracking during application or on storage. Suitable plasticizers include diethyl phthalate, tributyl citrate and triacetin.
[0416] Composition H (Enteric-Coated Controlled Release Tablet)
[0417] Enteric-coated tablets of Composition F can be prepared by coating the tablets with 50 mg/tablet of an enteric polymer such as cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethyl-cellulose phthalate, or anionic polymers of methacrylic acid and methacrylic acid methyl ester (Eudragit L). Except for Eudragit L, these polymers should also include 10% (by weight of the quantity of polymer used) of a plasticizer to prevent membrane cracking during application or on storage. Suitable plasticizers include diethyl phthalate, tributyl citrate and triacetin.
[0418] (ii) Capsule Compositions
[0419] Composition A
[0420] Capsules can be prepared by admixing the ingredients of Composition D above and filling two-part hard gelatin capsules with the resulting mixture. Composition B (infra) may be prepared in a similar manner.
9|
|
Composition B
mg/capsule
|
(a) Active ingredient250
(b) Lactose B.P.143
(c) Sodium Starch Glycollate25
(d) Magnesium Stearate2
420
|
[0421]
10
|
|
Composition C
|
mg/capsule
|
|
(a) Active ingredient
250
|
(b) Macrogol 4000 BP
350
|
600
|
|
[0422] Capsules can be prepared by melting the Macrogol 4000 BP, dispersing the active ingredient in the melt and filling-two-part hard gelatin capsules therewith.
11|
|
Composition D
mg/capsule
|
Active ingredient250
Lecithin100
Arachis Oil100
450
|
[0423] Capsules can be prepared by dispersing the active ingredient in the lecithin and arachis oil and filling soft, elastic gelatin capsules with the dispersion.
12|
|
Composition E (Controlled release capsule)
mg/capsule
|
(a) Active ingredient250
(b) Microcrystalline Cellulose125
(c) Lactose BP125
(d) Ethyl Cellulose 13
513
|
[0424] The controlled release capsule composition can be prepared by extruding mixed ingredients (a) to (c) using an extruder, then spheronising and drying the extrudate. The dried pellets are coated with a release controlling membrane (d) and filled into two-part, hard gelatin capsules.
13|
|
Composition F (Enteric capsule)
mg/capsule
|
(a) Active ingredient250
(b) Microcrystalline Cellulose125
(c) Lactose BP125
(d) Cellulose Acetate Phthalate 50
(e) Diethyl Phthalate 5
555
|
[0425] The enteric capsule composition can be prepared by extruding mixed ingredients (a) to (c) using an extruder, then spheronising and drying the extrudate. The dried pellets are coated with an enteric membrane (d) containing a plasticizer (e) and filled into two-part, hard gelatin capsules.
[0426] Composition G (Enteric-Coated Controlled Release Capsule)
[0427] Enteric capsules of Composition E can be prepared by coating the controlled-release pellets with 50 mg/capsule of an enteric polymer such as cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose phthalate, or anionic polymers of methacrylic acid and methacrylic acid methyl ester (Eudragit L). Except for Eudragit L, these polymers should also include 10% (by weight of the quantity of polymer used) of a plasticizer to prevent membrane cracking during application or on storage. Suitable plasticizers include diethyl phthalate, tributyl citrate and triacetin.
14|
|
(iii) Intravenous injection composition
|
|
Active ingredient0.200g
Sterile, pyrogen-free phosphate buffer (pH 9.0) to10ml
|
[0428] The active ingredient is dissolved in most of the phosphate buffer at 35-40° C., then made up to volume and filtered through a sterile micropore filter into sterile 10 ml glass vials (Type 1) which are sealed with sterile closures and overseals.
15|
|
(iv) Intramuscular injection composition
|
|
Active ingredient0.20g
Benzyl Alcohol0.10g
Glycofurol 751.45g
Water for Injection q.s. to3.00ml
|
[0429] The active ingredient is dissolved in the glycofurol. The benzyl alcohol is then added and dissolved, and water added to 3 ml. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml glass vials (Type 1).
16|
|
(v) Syrup composition
|
|
Active ingredient0.25g
Sorbitol Solution1.50g
Glycerol1.00g
Sodium Benzoate0.005g
Flavour0.0125ml
Purified Water q.s. to5.0ml
|
[0430] The sodium benzoate is dissolved in a portion of the purified water and the sorbitol solution added. The active ingredient is added and dissolved. The resulting solution is mixed with the glycerol and then made up to the required volume with the purified water.
17|
|
(vi) Suppository composition
mg/suppository
|
Active ingredient 250
Hard Fat, BP (Witepsol H15-Dynamit NoBel)1770
2020
|
[0431] One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45° C. maximum. The active ingredient is sifted through a 200 lm sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45° C., the remaining Witepsol H15 is added to the suspension which is stirred to ensure a homogenous mix. The entire suspension is then passed through a 250 lm stainless steel screen and, with continuous stirring, allowed to cool to 40° C. At a temperature of 38-40° C., 2.02 g aliquots of the mixture are filled into suitable plastic moulds and the suppositories allowed to cool to room temperature.
18|
|
(vii) Pessary composition
mg/pessary
|
Active ingredient (63lm)250
Anhydrous Dextrose380
Potato Starch363
Magnesium Stearate7
1000
|
[0432] The above ingredients are mixed directly and pessaries prepared by compression of the resulting mixture.
19|
|
(viii) Transdermal composition
|
|
Active ingredient200mg
Alcohol USP0.1ml
Hydroxyethyl cellulose
|
[0433] The active ingredient and alcohol USP are gelled with hydroxyethyl cellulose and packed in a transdermal device with a surface area of 10 cm2.
Claims
- 1. A compound of formula (I)
- 2. A compound according to claim 1 where Ar1 represents a substituted phenyl, naphthyl or 1,2,3,4-tetrahydronaphthyl group, where optional substitution is effected by R1.
- 3. A compound according to claim 1 or 2 where Ar1 is substituted by methylenedioxy or one or two groups independently selected from hydroxy, C1-4 alkyl, C1-4 alkoxy, —O—C0-4alkylene-R2, where R2 represents C1-4 perfluoroalkyl, a 5-6 membered heteroaromatic group or a C3-8cycloalkyl.
- 4. A compound according to any one of claims 1-3 where Ar2 is phenyl.
- 5. A compound according to any one of claims 1-4 where E is an n-butylene group.
- 6. A compound according to any one of claims 1-5 where X is an —N(H)CO— group.
- 7. A compound according to any one of claims 1-6 where Ar3 is phenyl substituted by a halogen, C1-4perfluoroalkyl, C1-4acyl, nitrile or C1-4alkylsulfonyl.
- 8. A compound according to claim 7 where Ar3 is phenyl substituted by a chloro or nitrile.
- 9. A compound of formula (Ia)
- 10. A compound of formula (Ib)
- 11. A compound selected from
4′-Trifluoromethyl-biphenyl-4-carboxylic acid {4-[4-(2-ethoxy-4-methyl-phenyl)-piperidin-1-yl]-butyl}-amide; 4′-Trifluoromethyl-biphenyl-4-carboxylic acid [4-[4-(2-cyclopropylmethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl]-amide; 4′-Chloro-biphenyl-4-carboxylic acid {4-[4-(1-methoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide; 4′-Chloro-biphenyl-4-carboxylic acid {4-[4-(2-methoxy-naphtalen-1-yl)-piperidin-1-yl]-butyl}-amide; 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(2-ethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-amide; 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(1-methoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide; 4′Trifluoromethyl-biphenyl-4-carboxylic acid {4-[4-(1-isobutoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide 4′-Trifluoromethyl-biphenyl-4-carboxylic acid {4-[4-(1-allyloxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide; 4′-Trifluoromethyl-biphenyl-4-carboxylic acid {4-[4-(1-propoxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide; 4′-Trifluoromethyl-biphenyl-4-carboxylic acid {4-[4-(1-Cyclopropylmethoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide; 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(1-methoxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide; 4′-Methanesulfonyl-biphenyl-4-carboxylic acid {4-[4-(2-ethoxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-amide; 4-Methyl-2-(4-trifluromethyl-phenyl)-thiazole-5-carboxylic acid {4-[4-(4-isopropyl-2-methoxy-phenyl)-piperidin-1-yl]-butyl}-amide; 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(2-hydroxy-4-ethyl-phenyl)-piperidin-1-yl]-butyl}-amide; 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(1-hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide; 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(1-hydroxy-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide; 4′-Acetyl-biphenyl-4-carboxylic acid {4-[4-(1-hydroxy-5,6,7,8-tetrahydro-naphtalen-2-yl)-piperidin-1-yl]-butyl}-amide; 4′-Cyano-biphenyl-4-carboxylic acid {4-[4-(2-hydroxy-4-methyl-phenyl)-piperidin-1-yl]-butyl}-amide; or a physiologically acceptable salt, solvate or derivative thereof.
- 12. Use of a compound according to any one of claims 1-11 in human medicine.
- 13. Use of a compound according to any one of claims 1-11 or a physiologically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions resulting from elevated circulating levels of LDL-cholesterol.
- 14. A method for the treatment of a mammal, including man, of conditions resulting from elevated circulating levels of LDL-cholesterol, comprising administration of an effective amount of a compound according to any one of claims 1-11 or a physiologically acceptable salt or solvate thereof.
- 15. A pharmaceutical composition which comprises at least one compound according to any one of claims 1-11 or a physiologically acceptable salt or solvate thereof, with one or more pharmaceutically acceptable carriers or excipients and optionally one or more further physiologically active agents.
- 16. A process for the preparation of compound of formula (I) comprising:
(A)—reaction of a compound of formula (II) with a compound of formula (III) 29where Xa and Xb are suitable reactants to form a group X; (B) reaction of a compound of formula (IV) with a compound of formula (XIII) 30where E−C1 (‘E minus C1’) means that the chain length of group E is one carbon less than that in the resulting compound (I), under standard reductive amination conditions; or (C) reaction of a different compound of formula (I).
PCT Information
| Filing Document |
Filing Date |
Country |
Kind |
| PCT/GB01/00159 |
1/15/2001 |
WO |
|
